{"content":"<li class=\"n-box-item date-title\" data-end=\"1504843199\" data-start=\"1504756800\" data-txt=\"Monday, December 23, 2019\">Thursday, September  7, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3294312\" data-ts=\"1504824565\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EFX\" target=\"_blank\">EFX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294312-three-equifax-execs-sold-stock-breach-was-revealed-sharesminus-12_4-updated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Three Equifax execs sold stock before breach was revealed; shares -12.4% (updated)</a></h4><ul>     <li>Three senior executives at Equifax (NYSE:<a href='https://seekingalpha.com/symbol/EFX' title='Equifax Inc.'>EFX</a>) <a href=\"https://www.bloomberg.com/news/articles/2017-09-07/three-equifax-executives-sold-stock-before-revealing-cyber-hack\" target=\"_blank\">sold shares</a> in the days after a <a href=\"https://seekingalpha.com/news/3294289-equifax-reports-massive-cyberattack-shares-6-percent-hours\" target=\"_blank\">historic security breach was discovered</a>, but before it was widely reported, Bloomberg notes.</li>     <li>The execs sold about $1.8M worth, and none of the shares are listed as being part of 10b5-1 scheduled trading plans.</li>     <li>Equifax shares are now <font color='red'>down 12.4%</font> after hours.</li>     <li>The breach was discovered by Equifax on July 29; three days after that, <a href=\"https://seekingalpha.com/filing/3648152\" target=\"_blank\">according to an SEC filing</a>, Chief Financial Officer John Gamble unloaded $946,374 worth of shares and Joseph Loughran (president of U.S. information solutions) exercised options to <a href=\"https://seekingalpha.com/filing/3648125\" target=\"_blank\">rid himself of $584,099 worth</a>.</li>     <li>The day after those two sales, Rodolfo Ploder, president of workforce solutions, <a href=\"https://seekingalpha.com/filing/3647951\" target=\"_blank\">sold $250,458 worth</a>.</li>     <li><strong>Updated:&nbsp;</strong>The company says that the three execs hadn't yet been informed of the incident, Bloomberg reports. They &ldquo;sold a small percentage of their Equifax shares,&rdquo; and \"had no knowledge that an intrusion had occurred at the time,&rdquo; Equifax says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294312\" data-linked=\"Three Equifax execs sold stock before breach was revealed; shares -12.4% (updated)\" data-tweet=\"$EFX - Three Equifax execs sold stock before breach was revealed; shares -12.4% (updated) https://seekingalpha.com/news/3294312-three-equifax-execs-sold-stock-breach-was-revealed-sharesminus-12_4-updated?source=tweet\" data-url=\"https://seekingalpha.com/news/3294312-three-equifax-execs-sold-stock-breach-was-revealed-sharesminus-12_4-updated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>82&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294305\" data-ts=\"1504821190\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRU\" target=\"_blank\">TRU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294305-transunionminus-2_7-after-attack-on-equifax\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TransUnion -2.7% after attack on Equifax</a></h4><ul><li>Equifax <a href=\"https://seekingalpha.com/news/3294289-equifax-reports-massive-cyberattack-shares-6-percent-hours\" target=\"_blank\">earlier disclosed a</a> cyberattack in which the sensitive data of up to 143M U.S. consumers may have been breached. Its shares are<font color='red'> lower by 6%&nbsp;</font>in after hours action.</li><li>TransUnion (NYSE:<a href='https://seekingalpha.com/symbol/TRU' title='TransUnion'>TRU</a>)&nbsp;<font color='red'>-2.7%</font>. Experian (<a href='https://seekingalpha.com/symbol/EXPGY' title='Experian plc ADR'>OTCQX:EXPGY</a>), Fair Isaac (NYSE:<a href='https://seekingalpha.com/symbol/FICO' title='Fair Isaac Corporation'>FICO</a>) no trades.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294305\" data-linked=\"TransUnion -2.7% after attack on Equifax\" data-tweet=\"$TRU $TRU $EXPGY - TransUnion -2.7% after attack on Equifax https://seekingalpha.com/news/3294305-transunionminus-2_7-after-attack-on-equifax?source=tweet\" data-url=\"https://seekingalpha.com/news/3294305-transunionminus-2_7-after-attack-on-equifax\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294301\" data-ts=\"1504820183\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294301-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/KURA' title='Kura Oncology'>KURA</a> <font color='green'>+27.7%</font>. <a href='https://seekingalpha.com/symbol/ZUMZ' title='Zumiez Inc.'>ZUMZ</a> <font color='green'>+10.2%</font>. <a href='https://seekingalpha.com/symbol/BV-OLD' title='Bazaarvoice'>BV-OLD</a> <font color='green'>+6.3%</font>. <a href='https://seekingalpha.com/symbol/AGX' title='Argan, Inc.'>AGX</a> <font color='green'>+4.0%</font>. <a href='https://seekingalpha.com/symbol/BBOX' title='Black Box Corporation'>BBOX</a> <font color='green'>+3.5%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/AOBC' title='American Outdoor Brands Corporation'>AOBC</a> <font color='red'>-17.0%</font>. <a href='https://seekingalpha.com/symbol/CHKE' title='Cherokee Inc.'>CHKE</a> <font color='red'>-16.1%</font>. <a href='https://seekingalpha.com/symbol/TNTR-OLD' title='Tintri, Inc.'>TNTR-OLD</a> <font color='red'>-8.6%</font>. <a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a> <font color='red'>-7.1%</font>. <a href='https://seekingalpha.com/symbol/EFX' title='Equifax Inc.'>EFX</a> <font color='red'>-5.7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294301\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$KURA $ZUMZ $BV-OLD - After Hours Gainers / Losers https://seekingalpha.com/news/3294301-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3294301-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294289\" data-ts=\"1504816870\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EFX\" target=\"_blank\">EFX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294289-equifax-reports-massive-cyberattack-shares-down-6-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Equifax reports massive cyberattack; shares down 6% after hours</a></h4><ul><li>The incident may have impacted 143M U.S. consumers, says the company. Information accessed mostly includes names, SS #'s, birth dates, addresses, and driver's license numbers.</li><li>In addition, credit card numbers for about 209K U.S. consumers were accessed.</li><li>The attack occurred from mid-May through July, and Equifax (NYSE:<a href='https://seekingalpha.com/symbol/EFX' title='Equifax Inc.'>EFX</a>) discovered it on July 29. The company also identified unauthorized access for certain U.K. and Canadian residents.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16935009-equifax-announces-cybersecurity-incident-involving-consumer-information\" target=\"_blank\">Press Release</a></li><li>Shares<font color='red'> -6%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3294289\" data-linked=\"Equifax reports massive cyberattack; shares down 6% after hours\" data-tweet=\"$EFX - Equifax reports massive cyberattack; shares down 6% after hours https://seekingalpha.com/news/3294289-equifax-reports-massive-cyberattack-shares-down-6-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3294289-equifax-reports-massive-cyberattack-shares-down-6-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294280\" data-ts=\"1504816057\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNSR\" target=\"_blank\">FNSR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294280-finisarminus-6_6-current-quarter-guidance-comes-up-light\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Finisar -6.6% as current-quarter guidance comes up light</a></h4><ul>   <li>Finisar (NASDAQ:<a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a>) has <font color='red'>fallen 6.6%</font> in after-hours trading following the release of <a href=\"https://seekingalpha.com/news/3294246-finisar-eps-line-beats-revenue\" target=\"_blank\">Q1 earnings</a> that came in mostly in line but saw revenues drop Q/Q and featured downbeat guidance for the current quarter.</li>    <li>Sales of datacom products fell 3.1% Q/Q on lower demand; sales of telecom products fell 8.1% Q/Q. Operating income fell 27% sequentially, to $29.9M.</li>    <li>For Q2 it's guiding to revenues of $322M-$342M (short of consensus for $370.3M) and non-GAAP EPS of $0.27-$0.33 (light of consensus for $0.50).</li><li>It's forecasting non-GAAP gross margin fo 33-34% and operating margin of 10-11%.</li>    <li><a href=\"http://edge.media-server.com/m/p/u7wee8eg\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16934922-finisar-announces-first-quarter-fiscal-2018-financial-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3294280\" data-linked=\"Finisar -6.6% as current-quarter guidance comes up light\" data-tweet=\"$FNSR - Finisar -6.6% as current-quarter guidance comes up light https://seekingalpha.com/news/3294280-finisarminus-6_6-current-quarter-guidance-comes-up-light?source=tweet\" data-url=\"https://seekingalpha.com/news/3294280-finisarminus-6_6-current-quarter-guidance-comes-up-light\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294268\" data-ts=\"1504815435\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZUMZ\" target=\"_blank\">ZUMZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294268-zumiez-higher-sales-growth-picks-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zumiez higher as sales growth picks up</a></h4><ul><li>Zumiez (NASDAQ:<a href='https://seekingalpha.com/symbol/ZUMZ' title='Zumiez Inc.'>ZUMZ</a>) posts a narrower-than-anticipated loss in Q2 on comparable sales growth of 47%.</li><li>Gross profit improved 30 bps to 31.3% of sales during the quarter.</li><li>Looking ahead, the retailer expects Q3 compable sales growth of 4% to 6% and total revenue of $236M to $241M vs. $228M consensus.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294258-zumiez-beats-0_04-revenue-line\" target=\"_blank\">Zumiez beats by $0.04,  revenue in-line</a> (Sept. 7)</li><li>ZUMZ&nbsp;<font color='green'>+9.50%</font>&nbsp;AH to $14.50.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294268\" data-linked=\"Zumiez higher as sales growth picks up\" data-tweet=\"$ZUMZ - Zumiez higher as sales growth picks up https://seekingalpha.com/news/3294268-zumiez-higher-sales-growth-picks-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3294268-zumiez-higher-sales-growth-picks-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294267\" data-ts=\"1504815414\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KURA\" target=\"_blank\">KURA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294267-kura-oncologys-lead-candidate-tipifarnib-successful-in-mid-stage-head-and-neck-cancer-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kura Oncology&#39;s lead candidate tipifarnib successful in mid-stage head and neck cancer study</a></h4><ul><li>A Phase 2 clinical trial assessing Kura Oncology's (NASDAQ:<a href='https://seekingalpha.com/symbol/KURA' title='Kura Oncology'>KURA</a>) tipifarnib in patients with HRAS-positive treatment-resistant squamous cell carcinomas of the head and neck &#40;HNSCC&#41; <a href=\"https://seekingalpha.com/pr/16934957-kura-oncology-announces-positive-phase-2-study-tipifarnib-hras-mutant-head-neck-cancer\" target=\"_blank\">met its primary endpoint</a> before the completion of enrollment.</li><li>The primary endpoint required at least four confirmed partial responses out of 18 patients. In the first six evaluable participants there were four partial responders and two with stable disease. The results will be submitted for presentation at a future medical conference.</li><li><a href=\"http://www.kuraoncology.com/pipeline/tipifarnib-hras/\" target=\"_blank\">Tipifarnib&nbsp;</a>inhibits an enzyme called farnesyl transferase. Interfering with its function inhibits protein farnesylation, a key signaling process in cancer initiation and development. Farnesyl transferase inhibitors have shown particular promise in blocking HRAS farnesylation.</li><li>The clinical development of tipifarnib is ongoing.</li><li>Shares jumped at the end of the session, ending the day up&nbsp;<font color='green'>22%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3248904-kuras-lead-candidate-tipifarnib-continues-demonstrate-treatment-benefit-mid-stage-study\" target=\"_blank\">Kura's lead candidate tipifarnib continues to demonstrate treatment benefit in mid-stage study; shares off 17% on profit taking</a> (March 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294267\" data-linked=\"Kura Oncology&#39;s lead candidate tipifarnib successful in mid-stage head and neck cancer study\" data-tweet=\"$KURA - Kura Oncology&#39;s lead candidate tipifarnib successful in mid-stage head and neck cancer study https://seekingalpha.com/news/3294267-kura-oncologys-lead-candidate-tipifarnib-successful-in-mid-stage-head-and-neck-cancer-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3294267-kura-oncologys-lead-candidate-tipifarnib-successful-in-mid-stage-head-and-neck-cancer-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294253\" data-ts=\"1504814707\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGC\" target=\"_blank\">RGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294253-theater-stocks-tossed-around-again\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Theater stocks tossed around again</a></h4><ul>     <li>It was a tough day for theater stocks after Disney dished out more details on its streaming service and Twenty-First Century Fox Film CEO Stacey Snider said at a media conference that premium video on demand on first-run movies will begin in as soon as six months to a year.</li><li>Regal Entertainment (NYSE:<a href='https://seekingalpha.com/symbol/RGC' title='Regal Entertainment Group'>RGC</a>)&nbsp;<font color='red'>fell 5.3%</font>, while shares of Cinemark (NYSE:<a href='https://seekingalpha.com/symbol/CNK' title='Cinemark Holdings, Inc'>CNK</a>)&nbsp;<font color='red'>peeled off 5.1%</font>. IMAX (NYSE:<a href='https://seekingalpha.com/symbol/IMAX' title='IMAX Corporation'>IMAX</a>)&nbsp;<font color='red'>dropped 3.3%</font>&nbsp;and AMC Entertainment (NYSE:<a href='https://seekingalpha.com/symbol/AMC' title='AMC Entertainment Holdings, Inc'>AMC</a>)&nbsp;<font color='red'>shed 4.2%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294198-media-stocks-slip-alongside-updates-disney-comcast\" target=\"_blank\">Media stocks slip alongside updates from Disney, Comcast</a> (Sept. 7)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294253\" data-linked=\"Theater stocks tossed around again\" data-tweet=\"$RGC $RGC $CNK - Theater stocks tossed around again https://seekingalpha.com/news/3294253-theater-stocks-tossed-around-again?source=tweet\" data-url=\"https://seekingalpha.com/news/3294253-theater-stocks-tossed-around-again\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>59&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294243\" data-ts=\"1504814404\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGEN\" target=\"_blank\">AGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294243-agenus-shows-bullish-action-ahead-of-next-weeks-ad-com-review-of-glaxo-shingles-vaccine\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agenus shows bullish action ahead of next week&#39;s Ad Com review of Glaxo shingles vaccine; shares up 10%</a></h4><ul><li>Agenus (<a href='https://seekingalpha.com/symbol/AGEN' title='Agenus'>AGEN</a> <font color='green'>+10.4%</font>) breaks out of short-term consolidation on 60% higher volume as it tries to claw back from July's selloff. Next Wednesday, September 13, the FDA's Vaccines and Related Biological Product Advisory Committee will <a href=\"https://www.fda.gov/AdvisoryCommittees/Calendar/ucm570421.htm\" target=\"_blank\">review </a>GlaxoSmithKline's marketing application for shingles vaccine Shingrix, which contains Agenus' QS-21 adjuvant Stimulon.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294243\" data-linked=\"Agenus shows bullish action ahead of next week&#39;s Ad Com review of Glaxo shingles vaccine; shares up 10%\" data-tweet=\"$AGEN - Agenus shows bullish action ahead of next week&#39;s Ad Com review of Glaxo shingles vaccine; shares up 10% https://seekingalpha.com/news/3294243-agenus-shows-bullish-action-ahead-of-next-weeks-ad-com-review-of-glaxo-shingles-vaccine?source=tweet\" data-url=\"https://seekingalpha.com/news/3294243-agenus-shows-bullish-action-ahead-of-next-weeks-ad-com-review-of-glaxo-shingles-vaccine\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294242\" data-ts=\"1504814242\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMS\" target=\"_blank\">BMS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294242-bemisplus-10-after-amcor-reportedly-explores-takeover\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bemis +10% after Amcor reportedly explores takeover</a></h4><ul>     <li>Bemis (<a href='https://seekingalpha.com/symbol/BMS' title='Bemis Company, Inc.'>BMS</a> <font color='green'>+9.9%</font>) surges following a Bloomberg report that Amcor (<a href='https://seekingalpha.com/symbol/AMCRY' title='Amcor Ltd. ADR'>OTCPK:AMCRY</a> <font color='green'>+1.6%</font>) is working with advisers to <a href=\"https://www.bloomberg.com/news/articles/2017-09-07/amcor-is-said-to-explore-takeover-of-packaging-maker-bemis\" target=\"_blank\">explore a takeover</a> of the packaging maker.</li>     <li>Considerations are at an early stage, and it is unclear whether Amcor has made an initial approach to BMS, according to the report.</li>     <li>Shares of other top global providers of plastic packaging also enjoy a bump: <a href='https://seekingalpha.com/symbol/SEE' title='Sealed Air Corporation'>SEE</a> <font color='green'>+0.8%</font>, <a href='https://seekingalpha.com/symbol/BERY' title='Berry Plastics Group, Inc.'>BERY</a> <font color='green'>+0.7%</font>, <a href='https://seekingalpha.com/symbol/SON' title='Sonoco Products Co.'>SON</a> <font color='green'>+0.3%</font>, <a href='https://seekingalpha.com/symbol/SLGN' title='Silgan Holdings, Inc.'>SLGN</a> <font color='green'>+1%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294242\" data-linked=\"Bemis +10% after Amcor reportedly explores takeover\" data-tweet=\"$BMS $AMCR $SEE - Bemis +10% after Amcor reportedly explores takeover https://seekingalpha.com/news/3294242-bemisplus-10-after-amcor-reportedly-explores-takeover?source=tweet\" data-url=\"https://seekingalpha.com/news/3294242-bemisplus-10-after-amcor-reportedly-explores-takeover\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294239\" data-ts=\"1504814173\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/S\" target=\"_blank\">S</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294239-radioshack-reorg-clears-court-hurdle-suit-pending-against-sprint\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RadioShack reorg clears court hurdle; suit pending against Sprint</a></h4><ul>   <li>A Chapter 11 exit plan for RadioShack cleared its preliminary court review today, which could mean some <a href=\"www.wsj.com/articles/radioshack-reorganization-clears-first-court-hurdle-1504811526\" target=\"_blank\">unlikely semblance of survival</a> for a former retail icon that filed for bankruptcy twice in just a few years.</li>    <li>The plan would leave the company with online operations, independent dealers and \"between zero and 28\" company-owned stores.</li>    <li>Under the plan, though, the chief source of recovery for unpaid creditors will be litigation against Sprint (<a href=\"http://seekingalpha.com/symbol/S\" target=\"_blank\">S</a> <font color='red'>-1.9%</font>), which a lawsuit blames for the collapse due to an allegedly forced pact between the two just before the Chapter 11 filing.</li>    <li>A partnership between Sprint and RadioShack led to Sprint setting up stores-within-stores to sell phones and draw traffic.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294239\" data-linked=\"RadioShack reorg clears court hurdle; suit pending against Sprint\" data-tweet=\"$S - RadioShack reorg clears court hurdle; suit pending against Sprint https://seekingalpha.com/news/3294239-radioshack-reorg-clears-court-hurdle-suit-pending-against-sprint?source=tweet\" data-url=\"https://seekingalpha.com/news/3294239-radioshack-reorg-clears-court-hurdle-suit-pending-against-sprint\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294236\" data-ts=\"1504813550\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPRO\" target=\"_blank\">GPRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294236-jpmorgan-raises-gopro-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan raises GoPro price target</a></h4><ul><li>        JPMorgan raises its GoPro (NASDAQ:<a href='https://seekingalpha.com/symbol/GPRO' title='GoPro'>GPRO</a>) price target from $13 to $15 and maintains an Overweight rating.</li><li>               Analyst Paul Coster is optimistic about the stock due to the potential return to full-year profitability due to demand growth, cost containment, and solidly executed product launches.&nbsp;</li><li>               EPS estimates increased: FY17, -$0.02 (from -$0.07); FY18, $0.57 (from $0.54); FY19, $0.94 (from $0.93).&nbsp;</li><li>               Source:<a href=\"https://www.streetinsider.com/Analyst+Comments/GoPro+%28GPRO%29+PT+Raised+to+%2415+at+JPMorgan%2C+Raises+EPS+Estimates/13275602.html\" target=\"_blank\"> StreetInsider</a>&nbsp;</li><li>               GoPro shares are&nbsp;<font color='green'>up 12.47%</font>.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294073-gopro-shares-14_6-percent-updating-q3-guidance\" target=\"_blank\">GoPro shares up 14.6% after updating Q3 guidance</a> (Sept. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294236\" data-linked=\"JPMorgan raises GoPro price target\" data-tweet=\"$GPRO - JPMorgan raises GoPro price target https://seekingalpha.com/news/3294236-jpmorgan-raises-gopro-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3294236-jpmorgan-raises-gopro-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294229\" data-ts=\"1504811142\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JW.A\" target=\"_blank\">JW.A</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294229-wileyminus-3_2-publishing-drags-on-profits\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wiley -3.2% as publishing drags on profits</a></h4><ul>   <li>John Wiley &amp; Sons (NYSE:<a href='https://seekingalpha.com/symbol/JW.A' title='John Wiley & Sons, Inc.'>JW.A</a>) is <font color='red'>off 3.2%</font> today after its <a href=\"https://seekingalpha.com/news/3294081-john-wiley-and-sons-misses-0_03-beats-revenue\" target=\"_blank\">Q1 earnings</a> came up short on profits.</li>    <li>Adjusted EPS was up 9%, but fell 5% in constant currency. Revenue gains of 1.8% were driven mainly by contributions from its acquisition of Atypon.</li>    <li>Revenue breakout: Research, $223.6M (up 8%); Publishing, $131.3M (down 9%); Solutions, $56.5M (up 9%)</li>    <li>&ldquo;We are realigning our cost base, reallocating resources, reinvesting in specific growth areas, and focusing on culture, productivity, and customer engagement &ndash; all of which should benefit us in fiscal 2019 and beyond,\" says interim CEO Matthew Kissner.</li>    <li>For the full year, it's reaffirming guidance of flat revenues and adjusted operating income, and a low-single-digit percentage decline in adjusted EPS. It's forecasting cash from operations of $350M or more, and capex to be slightly lower than last year's $148.3M.</li>    <li><a href=\"https://seekingalpha.com/pr/16933950-wiley-reports-first-quarter-2018-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3294229\" data-linked=\"Wiley -3.2% as publishing drags on profits\" data-tweet=\"$JW.A $JW.B - Wiley -3.2% as publishing drags on profits https://seekingalpha.com/news/3294229-wileyminus-3_2-publishing-drags-on-profits?source=tweet\" data-url=\"https://seekingalpha.com/news/3294229-wileyminus-3_2-publishing-drags-on-profits\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294225\" data-ts=\"1504810716\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294225-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/EGAN' title='eGain Communications Corp.'>EGAN</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/MVIS' title='Microvision, Inc.'>MVIS</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/AVNW' title='Aviat Networks, Inc.'>AVNW</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/SQNS' title='Sequans Communications'>SQNS</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/FIT' title='Fitbit, Inc.'>FIT</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AIRG' title='Airgain'>AIRG</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/PDVW' title='pdvWireless, Inc.'>PDVW</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/HIMX' title='Himax Technologies, Inc.'>HIMX</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/IPDN' title='Professional Diversity Network'>IPDN</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/LXFT' title='Luxoft Holding Inc'>LXFT</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294225\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$EGAN $MVIS $AVNW - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3294225-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3294225-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294218\" data-ts=\"1504808619\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWTR\" target=\"_blank\">TWTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294218-congressional-russian-investigation-aims-twitter-testimony\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Congressional Russian investigation aims at Twitter testimony</a></h4><ul>   <li>Yesterday Facebook testified to Congress about Russian-originated <a href=\"https://seekingalpha.com/news/3293956-facebook-finds-six-figures-russian-election-related-ad-spend-updated\" target=\"_blank\">activity on its platform</a> tied to the 2016 presidential election; <a href=\"https://www.wsj.com/articles/twitter-is-expected-to-brief-senate-panel-on-activity-by-russians-1504806299\" target=\"_blank\">next it may be Twitter's</a> (<a href=\"http://seekingalpha.com/symbol/TWTR\" target=\"_blank\">TWTR</a> <font color='green'>+2.7%</font>) turn.</li>    <li>Sen. Mark Warner, vice chairman of the Senate Intelligence Committee, says he's been in touch with the company and expects it to answer the committee's questions.</li>    <li>The new focus on social media is a new front in the congressional investigation. It could mean new pressure on Twitter and Facebook to crack down harder on misinformation and false accounts.</li>    <li>Yesterday, Facebook noted nearly 500 fake accounts possibly linked to Russia had spent six figures mainly aimed at divisive political ads meant to inflame public opinion.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294218\" data-linked=\"Congressional Russian investigation aims at Twitter testimony\" data-tweet=\"$TWTR - Congressional Russian investigation aims at Twitter testimony https://seekingalpha.com/news/3294218-congressional-russian-investigation-aims-twitter-testimony?source=tweet\" data-url=\"https://seekingalpha.com/news/3294218-congressional-russian-investigation-aims-twitter-testimony\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294216\" data-ts=\"1504808435\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294216-trucking-sector-seen-benefiting-from-tesla-factor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trucking sector seen benefiting from Tesla factor</a></h4><ul>     <li>Morgan Stanley takes a deep dive into the impact Tesla (<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a> <font color='green'>+1.4%</font>) could have in trucking with its upcoming EV truck announcement.</li>     <li>The firm thinks Tesla will announce partners at the event, which could include large truck carriers and shippers. Schneider National (NYSE:<a href='https://seekingalpha.com/symbol/SNDR' title='Schneider National'>SNDR</a>), Ryder (NYSE:<a href='https://seekingalpha.com/symbol/R' title='Ryder System, Inc.'>R</a>), FedEx (NYSE:<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a>), XPO Logistics (NYSEMKT:<a href='https://seekingalpha.com/symbol/XPO' title='XPO Logistics, Inc'>XPO</a>) and US Xpress are all mentioned by MS as potential test partners.</li>     <li>Based on its history, Morgan Stanley thinks Tesla could start taking orders immediately after the event with a $5K deposit.</li>     <li>Sector look from analysts Ravi Shanker and Adam Jonas:&nbsp;\"A rush by truck carriers to place Tesla truck orders and other OEMs to launch similar trucks could also be viewed by the market/investors as a key catalyst to the intelligent trucking thesis becoming real. We believe being announced as an early launch partner is likely to drive a multiple re-rating &ndash; SNDR, XPO, <a href='https://seekingalpha.com/symbol/ODFL' title='Old Dominion Freight Line, Inc.'>ODFL</a> and <a href='https://seekingalpha.com/symbol/WERN' title='Werner Enterprises, Inc.'>WERN</a> are our top trucking picks.\"</li><li>Other freight transportation companies to watch: <a href='https://seekingalpha.com/symbol/ARCB' title='ArcBest Corporation'>ARCB</a>, <a href='https://seekingalpha.com/symbol/CHRW' title='C.H. Robinson Worldwide Inc.'>CHRW</a>, <a href='https://seekingalpha.com/symbol/ECHO' title='Echo Global Logistics, Inc.'>ECHO</a>, <a href='https://seekingalpha.com/symbol/UPS' title='United Parcel Service, Inc.'>UPS</a>, SWFT, <a href='https://seekingalpha.com/symbol/LSTR' title='Landstar System, Inc.'>LSTR</a>, <a href='https://seekingalpha.com/symbol/JBHT' title='J.B. Hunt Transport Services, Inc.'>JBHT</a>, <a href='https://seekingalpha.com/symbol/KNX' title='Knight-Swift Transportation Holdings Inc.'>KNX</a>, <a href='https://seekingalpha.com/symbol/HTLD' title='Heartland Express, Inc.'>HTLD</a>.</li><li>As for Tesla, Morgan Stanley has a bull case price target of $526, a bear case price target of $175 and a base case PT of $317.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294216\" data-linked=\"Trucking sector seen benefiting from Tesla factor\" data-tweet=\"$TSLA $TSLA $SNDR - Trucking sector seen benefiting from Tesla factor https://seekingalpha.com/news/3294216-trucking-sector-seen-benefiting-from-tesla-factor?source=tweet\" data-url=\"https://seekingalpha.com/news/3294216-trucking-sector-seen-benefiting-from-tesla-factor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>154&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294211\" data-ts=\"1504807270\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294211-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CDXC' title='ChromaDex Inc.'>CDXC</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/MTRX' title='Matrix Service Company'>MTRX</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/HOS' title='Hornbeck Offshore Services, Inc.'>HOS</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/CGG-OLD' title='CGG'>CGG-OLD</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GURE' title='GULF RESOURCES INC'>GURE</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/CRZO' title='Carrizo Oil & Gas, Inc.'>CRZO</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/REN' title='Resolute Energy Corporation'>REN</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/WLL' title='Whiting Petroleum Corporation'>WLL</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/AM' title='Antero Midstream Partners'>AM</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294211\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$CDXC $MTRX $YTEN - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3294211-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3294211-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294209\" data-ts=\"1504807226\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSA\" target=\"_blank\">PSA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294209-self-storage-names-continue-hurricane-run\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Self-storage names continue hurricane run</a></h4><ul><li>Each name in the group is&nbsp;<font color='green'>higher by more than 1%&nbsp;</font>today.</li><li>Gains since August 18: Public Storage (NYSE:<a href='https://seekingalpha.com/symbol/PSA' title='Public Storage'>PSA</a>)&nbsp;<font color='green'>8.5%</font>, Extra Space Storage (NYSE:<a href='https://seekingalpha.com/symbol/EXR' title='Extra Space Storage, Inc.'>EXR</a>)&nbsp;<font color='green'>7%</font>, CubeSmart (NYSE:<a href='https://seekingalpha.com/symbol/CUBE' title='CubeSmart Common Shares'>CUBE</a>)&nbsp;<font color='green'>9.4%</font>, Life Storage&nbsp;<font color='green'>11.2%</font>, National Storage (NYSE:<a href='https://seekingalpha.com/symbol/NSA' title='National Storage Affiliates Trust'>NSA</a>)&nbsp;<font color='green'>8.9%</font>.</li><li>Jernigan Capital (NYSE:<a href='https://seekingalpha.com/symbol/JCAP' title='Jernigan Capital'>JCAP</a>) is a supplier of capital to the industry. It's&nbsp;<font color='green'>up 1.9%&nbsp;</font>today and&nbsp;<font color='green'>nearly 5%</font>&nbsp;since Aug. 18.</li><li>At least a couple of players still have a handful of locations closed post-Harvey, but all will be seeing boosted demand in affected states.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294209\" data-linked=\"Self-storage names continue hurricane run\" data-tweet=\"$PSA $PSA $EXR - Self-storage names continue hurricane run https://seekingalpha.com/news/3294209-self-storage-names-continue-hurricane-run?source=tweet\" data-url=\"https://seekingalpha.com/news/3294209-self-storage-names-continue-hurricane-run\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294207\" data-ts=\"1504806124\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATVI\" target=\"_blank\">ATVI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294207-blizzard-launching-esports-venue-on-tonight-show-stomping-grounds\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blizzard launching esports venue on &#39;Tonight Show&#39; stomping grounds</a></h4><ul>   <li>Activision Blizzard (<a href=\"http://seekingalpha.com/symbol/ATVI\" target=\"_blank\">ATVI</a> <font color='green'>+2.6%</font>) has formally announced an esports venue that will live in the former home of legendary late-night programming.</li>    <li>Its Blizzard Entertainment wing has unveiled <a href=\"https://seekingalpha.com/pr/16934638-blizzard-entertainment-establishes-state-art-live-event-destination-blizzard-arena-los\" target=\"_blank\">Blizzard Arena Los Angeles</a>, set in Burbank Studios (home to <i>The Tonight Show</i> broadcasts hosted by Johnny Carson and Jay Leno), planned to open Oct. 7.</li>    <li>The venue will host a schedule of live competition including <i>Overwatch</i> League and <i>Hearthstone</i> Championship Tour as well as playoffs around <i>Heroes of the Storm</i> and <i>World of Warcraft.</i></li>    <li>The facilities sport multiple sound stages, control rooms and practice facilities, Blizzard says, and is meant to support a year-round slate of events.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294207\" data-linked=\"Blizzard launching esports venue on &#39;Tonight Show&#39; stomping grounds\" data-tweet=\"$ATVI - Blizzard launching esports venue on &#39;Tonight Show&#39; stomping grounds https://seekingalpha.com/news/3294207-blizzard-launching-esports-venue-on-tonight-show-stomping-grounds?source=tweet\" data-url=\"https://seekingalpha.com/news/3294207-blizzard-launching-esports-venue-on-tonight-show-stomping-grounds\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294203\" data-ts=\"1504805081\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNI\" target=\"_blank\">MNI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294203-mcclatchy-drawing-56_75m-from-pair-of-property-deals\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">McClatchy drawing $56.75M from pair of property deals</a></h4><ul>   <li>McClatchy (<a href=\"http://seekingalpha.com/symbol/MNI\" target=\"_blank\">MNI</a> <font color='red'>-3.7%</font>) has wrapped up a <a href=\"https://www.bizjournals.com/sacramento/news/2017/09/07/mcclatchy-completes-property-deals-in-sacramento.html?ana=yahoo&amp;yptr=yahoo\" target=\"_blank\">pair of property deals</a> that will bring in $56.75M.</li>    <li>It's engaged in a sale-leaseback of the home of <i>The Sacramento Bee</i> with Shopoff Advisors, which will include initial annual rents of $4.365M over a 15-year period. It also wrapped the sale of building and land that's home to <i>The Kansas City Star,</i> to 1729 Grand Boulevard LLC.</li>    <li>The debt-heavy company sees in increase in cash to $127M with the deals, and it reduced debt by more than $18M.</li>    <li>McClatchy now has no material debt coming due until 2022.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294203\" data-linked=\"McClatchy drawing $56.75M from pair of property deals\" data-tweet=\"$MNI - McClatchy drawing $56.75M from pair of property deals https://seekingalpha.com/news/3294203-mcclatchy-drawing-56_75m-from-pair-of-property-deals?source=tweet\" data-url=\"https://seekingalpha.com/news/3294203-mcclatchy-drawing-56_75m-from-pair-of-property-deals\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294202\" data-ts=\"1504804944\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HRC\" target=\"_blank\">HRC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294202-stifel-likes-hill-rom-sees-9-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stifel likes Hill-Rom, sees 9% upside</a></h4><ul><li>In a note, Stifel says it likes the progress Hill-Rom (<a href='https://seekingalpha.com/symbol/HRC' title='Hill-Rom Holdings, Inc.'>HRC</a> <font color='green'>+0.9%</font>) is making as it transitions to more profitable and higher growth businesses, exemplified by its acquisitions of Welch Allyn and Mortara. Despite acknowledging that the transformation will take time to bear fruit, it rates the stock a Buy with an $84 (9% upside) price target.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3294202\" data-linked=\"Stifel likes Hill-Rom, sees 9% upside\" data-tweet=\"$HRC - Stifel likes Hill-Rom, sees 9% upside https://seekingalpha.com/news/3294202-stifel-likes-hill-rom-sees-9-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3294202-stifel-likes-hill-rom-sees-9-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294200\" data-ts=\"1504804491\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHRS\" target=\"_blank\">CHRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294200-coherus-loses-challenge-to-abbvie-humira-patent-shares-down-5-abbvie-up-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coherus loses challenge to AbbVie Humira patent; shares down 5%; AbbVie up 6%</a></h4><ul><li>Coherus BioSciences (<a href='https://seekingalpha.com/symbol/CHRS' title='Coherus BioSciences'>CHRS</a> <font color='red'>-4.9%</font>) is under pressure on modestly higher volume after it <a href=\"https://seekingalpha.com/pr/16934622-coherus-biosciences-provides-update-619-ipr-institution-decision\" target=\"_blank\">announced </a>that USPTO denied all four of its petitions for Inter Partes review of AbbVie's (<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a> <font color='green'>+6.2%</font>) U.S. Patent No. 9,085,619 protecting HUMIRA (adalimumab).</li><li>CEO Denny Lanfear says, &ldquo;While we are disappointed by this outcome, we continue to develop and refine our legal strategies for addressing any patents, including formulation patents, that AbbVie may assert in District Court proceedings.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3294200\" data-linked=\"Coherus loses challenge to AbbVie Humira patent; shares down 5%; AbbVie up 6%\" data-tweet=\"$CHRS $CHRS $ABBV - Coherus loses challenge to AbbVie Humira patent; shares down 5%; AbbVie up 6% https://seekingalpha.com/news/3294200-coherus-loses-challenge-to-abbvie-humira-patent-shares-down-5-abbvie-up-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3294200-coherus-loses-challenge-to-abbvie-humira-patent-shares-down-5-abbvie-up-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294199\" data-ts=\"1504804012\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294199-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/IRT' title='Independence Realty Trust'>IRT</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/RCG' title='RENN Global Entrepreneurs Fund'>RCG</a> <font color='green'>+5%</font>.<a href='https://seekingalpha.com/symbol/SGLB' title='Sigma Labs, Inc.'>SGLB</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/UVE' title='Universal Insurance Holdings, Inc'>UVE</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/AHL' title='Aspen Insurance Holdings Limited'>AHL</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/BCRH' title='Blue Capital Reinsurance Holdings Ltd.'>BCRH</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/HCI' title='HCI Group, Inc.'>HCI</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/UIHC' title='United Insurance Holdings Corp.'>UIHC</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294199\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$IRT $RCG $SGLB - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3294199-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3294199-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294198\" data-ts=\"1504803883\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DIS\" target=\"_blank\">DIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294198-media-stocks-slip-alongside-updates-from-disney-comcast\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Media stocks slip alongside updates from Disney, Comcast</a></h4><ul>   <li>Media stocks are moving lower alongside a decline in Disney (<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a> <font color='red'>-3.9%</font>) spurred by Bob Iger's comments about a late-2019 launch of its streaming service and expectations for <a href=\"https://seekingalpha.com/news/3294168-disney-ceo-marvel-star-wars-part-streaming-service\" target=\"_blank\">profits in line with last year</a>.</li>    <li>Fellow big-four broadcaster Comcast (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>), owner of NBCUniversal, is <font color='red'>down 6.4%</font> after giving its own <a href=\"https://seekingalpha.com/news/3294187-comcast-minus-6_3-percent-warning-heavy-video-subscriber-decline\" target=\"_blank\">investor-conference warning</a> of declining video subscribers. <a href='https://seekingalpha.com/symbol/CBS' title='CBS Corporation'>CBS</a>, meanwhile, has turned <font color='red'>down 3.8%</font>, and Twenty-First Century Fox (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='red'>-3.9%</font>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='red'>-4.1%</font>) is down as well.</li>    <li>Viacom (<a href='https://seekingalpha.com/symbol/VIA' title='Viacom Inc.'>VIA</a> <font color='red'>-2.2%</font>, <a href='https://seekingalpha.com/symbol/VIAB' title='Viacom Inc.'>VIAB</a> <font color='red'>-4.2%</font>) is lower and Discovery Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/DISCA' title='Discovery Inc A'>DISCA</a>) is <font color='red'>off 3%</font>; AMC Networks (NASDAQ:<a href='https://seekingalpha.com/symbol/AMCX' title='AMC Networks Inc.'>AMCX</a>) has <font color='red'>slipped 2.9%</font>.</li>    <li>Bucking the media decline: Time Warner (NYSE:<a href='https://seekingalpha.com/symbol/TWX' title='Time Warner Inc.'>TWX</a>), <font color='green'>up 0.1%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294198\" data-linked=\"Media stocks slip alongside updates from Disney, Comcast\" data-tweet=\"$DIS $DIS $CMCSA - Media stocks slip alongside updates from Disney, Comcast https://seekingalpha.com/news/3294198-media-stocks-slip-alongside-updates-from-disney-comcast?source=tweet\" data-url=\"https://seekingalpha.com/news/3294198-media-stocks-slip-alongside-updates-from-disney-comcast\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294190\" data-ts=\"1504802684\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PAC\" target=\"_blank\">PAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294190-grupo-aeroportuario-rallies-after-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Grupo Aeroportuario rallies after upgrade</a></h4><ul> <li>Grupo Aeroportuario Del Pacifico (<a href='https://seekingalpha.com/symbol/PAC' title='Grupo Aeroportuario del Pacifico, S.A.B de C.V.'>PAC</a> <font color='green'>+2.1%</font>) trades higher aftre Scotiabank upgrades the airport operator to Outperform from Sector Perform. The firm sets a price target of $110 on PAC.</li> <li>Earlier today, Grupo Aeroportuario reported a 10% increase in terminal passengers during August, which included a few days of Hurricane Harvey impact.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3294190\" data-linked=\"Grupo Aeroportuario rallies after upgrade\" data-tweet=\"$PAC - Grupo Aeroportuario rallies after upgrade https://seekingalpha.com/news/3294190-grupo-aeroportuario-rallies-after-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3294190-grupo-aeroportuario-rallies-after-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294187\" data-ts=\"1504802488\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMCSA\" target=\"_blank\">CMCSA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294187-comcastminus-6_3-warning-of-heavy-video-subscriber-decline\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Comcast -6.3%, warning of heavy video subscriber decline</a></h4><ul>   <li>Comcast (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>) has <font color='red'>tumbled 6.3%</font> after warning that it expects to lose 100,000-150,000 video subscribers in Q3, vs. expectations for a gain -- a decline it attributes to competition and Hurricane Harvey.</li>    <li>Speaking at an investor conference, Comcast's Matt Strauss says the current quarter is the \"most competitive in recent memory,\" though financials should be in line.</li>    <li>He also said the company's \"very open\" to carrying <a href=\"https://seekingalpha.com/news/3294168-disney-ceo-marvel-star-wars-part-streaming-service\" target=\"_blank\">new services from Disney</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294187\" data-linked=\"Comcast -6.3%, warning of heavy video subscriber decline\" data-tweet=\"$CMCSA - Comcast -6.3%, warning of heavy video subscriber decline https://seekingalpha.com/news/3294187-comcastminus-6_3-warning-of-heavy-video-subscriber-decline?source=tweet\" data-url=\"https://seekingalpha.com/news/3294187-comcastminus-6_3-warning-of-heavy-video-subscriber-decline\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294186\" data-ts=\"1504802479\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXEL\" target=\"_blank\">EXEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294186-exelixis-down-9-on-bristol-myers-successful-study-of-opdivo-yervoy-in-rcc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Exelixis down 9% on Bristol-Myers&#39; successful study of Opdivo + Yervoy in RCC</a></h4><ul><li>Exelixis (<a href='https://seekingalpha.com/symbol/EXEL' title='Exelixis, Inc.'>EXEL</a> <font color='red'>-8.8%</font>) is under pressure in apparent response to Bristol-Myers Squibb's announcement of positive results in a Phase 3 clinical trial assessing the combination of Opdivo and Yervoy in patients with advanced renal cell carcinoma.</li><li>Exelixis' top seller is CABOMETYX (cabozantinib), indicated for the same RCC patients as BMY's combo. It accounted for almost 82% of its Q2 revenues and 93% of its product sales.</li><li>In <a href=\"https://www.cabometyx.com/downloads/CABOMETYXUSPI.pdf\" target=\"_blank\">clinical studies</a>, RCC patients treated with CABOMETYX experienced median progression-free survival &#40;PFS&#41; of 7.4 months and median overall survival &#40;OS&#41; of 21.4 months in a second line setting.</li><li>In BMY's study, patients receiving the Opdivo/Yervoy regimen showed median PFS of 11.6 months while OS had not been reached.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294102-opdivo-yervoy-combo-extends-survival-late-stage-kidney-cancer-study-bristol-myers-2-percent\" target=\"_blank\">Opdivo-Yervoy combo extends survival in late-stage kidney cancer study; Bristol-Myers up 2% premarket</a> (Sept. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294186\" data-linked=\"Exelixis down 9% on Bristol-Myers&#39; successful study of Opdivo + Yervoy in RCC\" data-tweet=\"$EXEL - Exelixis down 9% on Bristol-Myers&#39; successful study of Opdivo + Yervoy in RCC https://seekingalpha.com/news/3294186-exelixis-down-9-on-bristol-myers-successful-study-of-opdivo-yervoy-in-rcc?source=tweet\" data-url=\"https://seekingalpha.com/news/3294186-exelixis-down-9-on-bristol-myers-successful-study-of-opdivo-yervoy-in-rcc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>39&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294185\" data-ts=\"1504802404\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294185-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a> <font color='green'>+43%</font>. <a href='https://seekingalpha.com/symbol/RH' title='RH'>RH</a> <font color='green'>+43%</font>. <a href='https://seekingalpha.com/symbol/EGAN' title='eGain Communications Corp.'>EGAN</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/CDXC' title='ChromaDex Inc.'>CDXC</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/ARCI' title='Appliance Recycling Centers of America, Inc.'>ARCI</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/XOMA' title='XOMA Corporation'>XOMA</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/SQNS' title='Sequans Communications'>SQNS</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/NH' title='NantHealth'>NH</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/AVNW' title='Aviat Networks, Inc.'>AVNW</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/MTNB' title='Matinas Biopharma Holdings, Inc.'>MTNB</a> <font color='green'>+16%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NCS' title='NCI Building Systems Inc.'>NCS</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/APOP' title='Cellect Biotechnology Ltd.'>APOP</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/UVE' title='Universal Insurance Holdings, Inc'>UVE</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/AIRG' title='Airgain'>AIRG</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/GURE' title='GULF RESOURCES INC'>GURE</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/BCRH' title='Blue Capital Reinsurance Holdings Ltd.'>BCRH</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/AHL' title='Aspen Insurance Holdings Limited'>AHL</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/DEST' title='Destination Maternity Corporation'>DEST</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/HCI' title='HCI Group, Inc.'>HCI</a> <font color='red'>-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294185\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$NLNK $RH $EGAN - Midday Gainers / Losers https://seekingalpha.com/news/3294185-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3294185-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294181\" data-ts=\"1504800995\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISCA\" target=\"_blank\">DISCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294181-discovery-launching-debt-offering-for-scripps-networks-bid-sharesminus-2_1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Discovery launching debt offering for Scripps Networks bid; shares -2.1%</a></h4><ul>   <li>Discovery Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/DISCA' title='Discovery Inc A'>DISCA</a>) is launching a <a href=\"https://seekingalpha.com/pr/16934016-discovery-communications-announces-debt-offering\" target=\"_blank\">public debt offering</a> in connection with its acquisition of Scripps Networks Interactive (NYSE:<a href='https://seekingalpha.com/symbol/SNI' title='Scripps Networks Interactive, Inc.'>SNI</a>).</li>    <li><a href='https://seekingalpha.com/symbol/DISCA' title='Discovery Inc A'>DISCA</a> has taken a dip, <font color='red'>down 2.1%</font>. <a href='https://seekingalpha.com/symbol/SNI' title='Scripps Networks Interactive, Inc.'>SNI</a> fell below the flat line, <font color='red'>down 0.2%</font>.</li>    <li>Few details are available; the company will offer one or more series of senior fixed-rate notes and senior floating-rate notes.</li>    <li>The proceeds are meant to supply part of the cash consideration for the buyout. The two came to a $14.6B cash-and-stock deal that they hope to close by early 2018.</li>    <li>Last month, it had <a href=\"https://seekingalpha.com/news/3289599-scripps-deal-discovery-boosts-revolver-sets-new-term-loan\" target=\"_blank\">increased the size of a revolving credit facility</a> and taken on a new term loan.</li>    <li>Joint book-runners are Goldman Sachs, Citigroup Global Markets and Credit Suisse Securities.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294181\" data-linked=\"Discovery launching debt offering for Scripps Networks bid; shares -2.1%\" data-tweet=\"$DISCA $DISCA $SNI - Discovery launching debt offering for Scripps Networks bid; shares -2.1% https://seekingalpha.com/news/3294181-discovery-launching-debt-offering-for-scripps-networks-bid-sharesminus-2_1?source=tweet\" data-url=\"https://seekingalpha.com/news/3294181-discovery-launching-debt-offering-for-scripps-networks-bid-sharesminus-2_1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294175\" data-ts=\"1504800390\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXSM\" target=\"_blank\">AXSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294175-interim-data-readout-from-two-late-stage-studies-of-axsomes-lead-candidate-axsminus-02\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interim data readout from two late-stage studies of Axsome&#39;s lead candidate AXS-02 expected by year-end; shares slip 11% on extended timeline</a></h4><ul><li>Thinly traded micro cap Axsome Therapeutics (<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics'>AXSM</a> <font color='red'>-10.9%</font>) is down on more than double normal volume, albeit on turnover of only 384K shares, in apparent response to its <a href=\"https://seekingalpha.com/pr/16933769-axsome-announces-createminus-1-interim-analysis-expected-year-end-2017\" target=\"_blank\">announcement </a>of the timing of interim analyses of two Phase 3 clinical trials assessing lead product candidate AXS-02, one of which represents a delay from a previous announcement.</li><li>The Independent Data Monitoring Committee &#40;IDMC&#41; will perform the analyses on the CREATE-1 study, evaluating AXS-02 in patients with complex regional pain syndrome, and COAST-1, in patients with knee osteoarthritis associated with bone marrow lesions. Both studies will be reviewed during the same meeting with reports expected by year-end or early January 2018.</li><li>The company previously announced that the interim analysis on COAST-1 would be completed in Q3.</li><li>AXS-02 (disodium zoledronate tetrahydrate) is an orally administered non-opioid pain therapeutic that inhibits bone turnover and localizes to regions of increased turnover (lesions in the bone marrow). It works by inhibiting an enzyme called farnesyl pyrophosphate synthase which, in turn, reduces the activity of bone cells called&nbsp;<a href=\"https://en.wikipedia.org/wiki/Osteoclast\" target=\"_blank\">osteoclasts</a>, cells that break down bone tissue in the critical process of bone regeneration.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3169765-axsomes-late-stage-study-underway-assessing-lead-product-candidate-arthritis-associated-knee\" target=\"_blank\">Axsome's late-stage study underway assessing lead product candidate in arthritis-associated knee pain</a> (March 28, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294175\" data-linked=\"Interim data readout from two late-stage studies of Axsome&#39;s lead candidate AXS-02 expected by year-end; shares slip 11% on extended timeline\" data-tweet=\"$AXSM - Interim data readout from two late-stage studies of Axsome&#39;s lead candidate AXS-02 expected by year-end; shares slip 11% on extended timeline https://seekingalpha.com/news/3294175-interim-data-readout-from-two-late-stage-studies-of-axsomes-lead-candidate-axsminus-02?source=tweet\" data-url=\"https://seekingalpha.com/news/3294175-interim-data-readout-from-two-late-stage-studies-of-axsomes-lead-candidate-axsminus-02\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294179\" data-ts=\"1504800097\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294179-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>    <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/GPRO' title='GoPro'>GPRO</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/OTIV' title='On Track Innovations Ltd'>OTIV</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/HOFT' title='Hooker Furniture Corporation'>HOFT</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/SGOC' title='SGOCO Techn'>SGOC</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/NOMD' title='Nomad Foods Ltd.'>NOMD</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/LEG' title='Leggett & Platt Inc.'>LEG</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/RACE' title='Ferrari N.V.'>RACE</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294179\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$GPRO $OTIV $HOFT - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3294179-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3294179-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294174\" data-ts=\"1504799277\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DCI\" target=\"_blank\">DCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294174-donaldsonminus-7-2018-guidance-disappoints\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Donaldson -7% as 2018 guidance disappoints</a></h4><ul>     <li>Filtration equipment maker Donaldson (<a href='https://seekingalpha.com/symbol/DCI' title='Donaldson Co Inc.'>DCI</a> <font color='red'>-7.3%</font>) sinks to six-month lows following a mixed <a href=\"https://seekingalpha.com/news/3294051-donaldson-misses-0_02-beats-revenue\" target=\"_blank\">FQ4 report</a> that included below consensus earnings but better than expected revenues.</li>     <li>DCI says Q4 gross margin was 34.8%, below the year-ago 35.2% rate, hurt by an unfavorable sales mix of products, higher raw materials costs and incremental freight charges.</li>     <li>DCI issues FY 2018 guidance at the low end of analyst estimates, seeing EPS of $1.79-$1.93 vs. $1.89 consensus and revenues gaining 4%-8% to $2.47B-$2.56B vs. $2.47B consensus.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294174\" data-linked=\"Donaldson -7% as 2018 guidance disappoints\" data-tweet=\"$DCI - Donaldson -7% as 2018 guidance disappoints https://seekingalpha.com/news/3294174-donaldsonminus-7-2018-guidance-disappoints?source=tweet\" data-url=\"https://seekingalpha.com/news/3294174-donaldsonminus-7-2018-guidance-disappoints\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294172\" data-ts=\"1504799188\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XOMA\" target=\"_blank\">XOMA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294172-xoma-builds-on-rally-up-17\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">XOMA builds on rally, up 17%</a></h4><ul><li>XOMA (<a href='https://seekingalpha.com/symbol/XOMA' title='XOMA Corporation'>XOMA</a> <font color='green'>+16.7%</font>) adds to its gevokizumab-stoked rally on more than a 5x surge in volume, albeit on turnover of only 527K shares. The stock has rallied 125% since the deal was announced several weeks ago.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3291764-xoma-licenses-gevokizumab-novartis-31m-plus-settlement-12m-debt\" target=\"_blank\">XOMA out-licenses gevokizumab to Novartis for $31M plus settlement of &euro;12M debt</a> (Aug. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294172\" data-linked=\"XOMA builds on rally, up 17%\" data-tweet=\"$XOMA - XOMA builds on rally, up 17% https://seekingalpha.com/news/3294172-xoma-builds-on-rally-up-17?source=tweet\" data-url=\"https://seekingalpha.com/news/3294172-xoma-builds-on-rally-up-17\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294171\" data-ts=\"1504798770\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIMX\" target=\"_blank\">HIMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294171-himax-down-6_4-on-oppenheimer-note-response-email\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Himax down 6.4% on Oppenheimer note, response email</a></h4><ul><li>        Himax Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/HIMX' title='Himax Technologies, Inc.'>HIMX</a>) shares&nbsp;<font color='red'>down 6.4%</font>&nbsp;after the company hits back at a negative note from Oppenheimer.</li><li>               Oppenheimer analyst Andrew Uerkwitz wrote a note saying that the company&rsquo;s growth opportunities weren&rsquo;t likely to pay off.&nbsp;</li><li>               Himax responds in an email to <a href=\"https://www.streetinsider.com/Analyst+Comments/Himax+Technologies+%28HIMX%29+Calls+Todays+Oppenheimer+Analyst+Note+Inaccurate+and+Misleading/13274482.html\" target=\"_blank\">StreetInsider</a>, in part: &ldquo;Himax management has not spoken to the analyst Andrew Uerkwitz from Oppenheimer for 5 months. Thus, we believe his report recently issued dated September 7, 2017 is INACCURATE and MISLEADING. This report does not represent the fact of our Company at all. We believe Andrew does not understand our business, period.&rdquo;&nbsp;</li><li>               Not d&eacute;j&agrave; vu: The company sent out a similar email about the same analyst back in July.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3278723-oppenheimer-downgrades-himax-himax-disagrees\" target=\"_blank\">Oppenheimer downgrades Himax, Himax disagrees</a> (July 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294171\" data-linked=\"Himax down 6.4% on Oppenheimer note, response email\" data-tweet=\"$HIMX - Himax down 6.4% on Oppenheimer note, response email https://seekingalpha.com/news/3294171-himax-down-6_4-on-oppenheimer-note-response-email?source=tweet\" data-url=\"https://seekingalpha.com/news/3294171-himax-down-6_4-on-oppenheimer-note-response-email\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294170\" data-ts=\"1504798364\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HCI\" target=\"_blank\">HCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294170-bounce-in-insurers-was-short-lived-berkshire-down-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bounce in insurers was short-lived; Berkshire down 2%</a></h4><ul><li>The property and casualty players and the reinsurers have suffered in the wake of Harvey and ahead of Irma. Thoughts that all that trouble was more than priced in led to a modest bounce yesterday, but that's reversing and more today.</li><li>Those with heavy Florida exposure are being hit the hardest: HCI Group (<a href='https://seekingalpha.com/symbol/HCI' title='HCI Group, Inc.'>HCI</a> <font color='red'>-9.5%</font>), Universal Insurance (<a href='https://seekingalpha.com/symbol/UVE' title='Universal Insurance Holdings, Inc'>UVE</a> <font color='red'>-10.2%</font>), United Insurance (<a href='https://seekingalpha.com/symbol/UIHC' title='United Insurance Holdings Corp.'>UIHC</a> <font color='red'>-8.1%</font>). Others: Travelers (<a href='https://seekingalpha.com/symbol/TRV' title='The Travelers Companies, Inc.'>TRV</a> <font color='red'>-2.2%</font>), Allstate (<a href='https://seekingalpha.com/symbol/ALL' title='Allstate Corporation'>ALL</a> <font color='red'>-1.5%</font>), Chubb (<a href='https://seekingalpha.com/symbol/CB' title='Chubb Ltd'>CB</a> <font color='red'>-1.4%</font>), Cincinnati Financial (<a href='https://seekingalpha.com/symbol/CINF' title='Cincinnati Financial Corporation'>CINF</a> <font color='red'>-1.8%</font>), Progressive (<a href='https://seekingalpha.com/symbol/PGR' title='Progressive Corporation'>PGR</a> <font color='red'>-1.7%</font>), Alleghany (<a href='https://seekingalpha.com/symbol/Y' title='Alleghany Corporation'>Y</a> <font color='red'>-2.6%</font>).</li><li>And the reinsurers, who presumably have taken on a good deal of the risk from the plain-vanilla players: Everest Re (<a href='https://seekingalpha.com/symbol/RE' title='Everest Re Group Ltd.'>RE</a> <font color='red'>-6.4%</font>), RenaissanceRe (<a href='https://seekingalpha.com/symbol/RNR' title='RenaissanceRe Holdings Ltd.'>RNR</a> <font color='red'>-4.7%</font>), Aspen Insurance (<a href='https://seekingalpha.com/symbol/AHL' title='Aspen Insurance Holdings Limited'>AHL</a> <font color='red'>-10.6%</font>), AXIS Capital (<a href='https://seekingalpha.com/symbol/AXS' title='Axis Capital Holdings Limited'>AXS</a> <font color='red'>-5.1%</font>), Arch Capital (<a href='https://seekingalpha.com/symbol/ACGL' title='Arch Capital Group Ltd.'>ACGL</a> <font color='red'>-3.3%</font>), Unum Group (<a href='https://seekingalpha.com/symbol/UNM' title='Unum Group'>UNM</a> <font color='red'>-2.2%</font>), Berkshire Hathaway (<a href='https://seekingalpha.com/symbol/BRK.A' title='Berkshire Hathaway A'>BRK.A</a> <font color='red'>-1.9%</font>), (<a href='https://seekingalpha.com/symbol/BRK.B' title='Berkshire Hathaway B'>BRK.B</a> <font color='red'>-1.9%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294170\" data-linked=\"Bounce in insurers was short-lived; Berkshire down 2%\" data-tweet=\"$HCI $HCI $UVE - Bounce in insurers was short-lived; Berkshire down 2% https://seekingalpha.com/news/3294170-bounce-in-insurers-was-short-lived-berkshire-down-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3294170-bounce-in-insurers-was-short-lived-berkshire-down-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294168\" data-ts=\"1504798044\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DIS\" target=\"_blank\">DIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294168-disney-ceo-marvel-star-wars-to-be-part-of-streaming-service\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Disney CEO: Marvel, Star Wars to be part of streaming service</a></h4><ul>     <li>Filling in a key detail on a planned launch of streaming services, Disney (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>) CEO Robert Iger says that movies from the company's Marvel and Star Wars units will go exclusively to its Disney-branded OTT service, rather than remaining on Netflix.</li>     <li>Speaking at an investor conference, Iger says those films will be available on top of Disney and Pixar films already mentioned as being part of the Disney service.</li><li>Fiscal 2017 EPS (ending in a few weeks) will be \"roughly in line\" with the previous year, he says.</li>     <li>Shares have taken a turn lower,<font color='red'> -2.5%.</font></li>     <li>Iger also narrowed the time frame for launch, now expected in \"late 2019.\"</li>     <li>Speaking of the company's <a href=\"https://twitter.com/benfritz/status/905810915664076800\" target=\"_blank\">relationship with cablecos</a>, Iger says \"Our relationships will remain relatively consistent for the near term, what happens in long term I&rsquo;m not sure.\"</li>     <li>The company will make <a href=\"https://twitter.com/benfritz/status/905813965791404038\" target=\"_blank\">4-5 original films a year</a> for the service, he says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294168\" data-linked=\"Disney CEO: Marvel, Star Wars to be part of streaming service\" data-tweet=\"$DIS - Disney CEO: Marvel, Star Wars to be part of streaming service https://seekingalpha.com/news/3294168-disney-ceo-marvel-star-wars-to-be-part-of-streaming-service?source=tweet\" data-url=\"https://seekingalpha.com/news/3294168-disney-ceo-marvel-star-wars-to-be-part-of-streaming-service\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>111&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294166\" data-ts=\"1504797987\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLNK\" target=\"_blank\">NLNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294166-newlinks-indoximod-shows-treatment-benefit-keytruda-in-mid-stage-melanoma-study-shares-ahead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NewLink&#39;s Indoximod shows treatment benefit with Keytruda in mid-stage melanoma study; shares ahead 32%</a></h4><ul><li>NewLink Genetics (<a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a> <font color='green'>+32.2%</font>) jumps on an 11x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/16933724-updated-data-indoximod-plus-keytruda-pembrolizumab-demonstrate-improvement-response-rate\" target=\"_blank\">announcement </a>of positive results from a Phase 2 clinical trial, NLG2103, evaluating the combination of indoximod and Merck's KEYTRUDA (pembrolizumab) in patients with advanced melanoma. The data will be presented at the Third International Cancer Immunotherapy Conference in Frankfurt/Mainz, Germany on September 9.</li><li>The results showed a 61% (n=31/51) objective response rate &#40;ORR&#41;, including 10 complete responders &#40;CR&#41;&nbsp;and 21 partial responders &#40;PR&#41;. The disease control rate (CR + PR + those with stable disease) was 80% (n=41/51). Median progression-free survival &#40;PFS&#41;&nbsp;was 12.9 months with a PFS rate at month 12 of 56%.</li><li>In the KEYNOTE-006 study assessing KEYTRUDA alone in melanoma patients, median PFS was 5.5 months (10 mg/kg every two weeks) and the ORR was 33%.</li><li>Three patients experienced grade 3 (serious) adverse events possibly related to indoximod.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294166\" data-linked=\"NewLink&#39;s Indoximod shows treatment benefit with Keytruda in mid-stage melanoma study; shares ahead 32%\" data-tweet=\"$NLNK - NewLink&#39;s Indoximod shows treatment benefit with Keytruda in mid-stage melanoma study; shares ahead 32% https://seekingalpha.com/news/3294166-newlinks-indoximod-shows-treatment-benefit-keytruda-in-mid-stage-melanoma-study-shares-ahead?source=tweet\" data-url=\"https://seekingalpha.com/news/3294166-newlinks-indoximod-shows-treatment-benefit-keytruda-in-mid-stage-melanoma-study-shares-ahead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294167\" data-ts=\"1504797863\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294167-rate-hike-odds-disappear\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rate hike odds disappear</a></h4><ul><li>Another rally at both ends of the yield curve has traders pricing in little more <a href=\"https://www.cmegroup.com/trading/interest-rates/stir/30-day-federal-fund.html\" target=\"_blank\">than a one-in-five chance</a> of any more Fed rate hikes in 2017. In fact, there's only one 25 basis point move being priced in between now and the end of 2018.</li><li>The 10-year Treasury yield today is down 6.7 basis points to a new post-election low of 2.039%.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/SHY' title='iShares 1-3 Year Treasury Bond ETF'>SHY</a>, <a href='https://seekingalpha.com/symbol/VGSH' title='Vanguard Short-Term Government Bond Index ETF'>VGSH</a>, <a href='https://seekingalpha.com/symbol/BIL' title='SPDR Barclays 1-3 Month T-Bill ETF'>BIL</a>, <a href='https://seekingalpha.com/symbol/SCHO' title='Schwab Short-Term U.S. Treasury ETF'>SCHO</a>, <a href='https://seekingalpha.com/symbol/SHV' title='iShares Short Treasury Bond ETF'>SHV</a>, <a href='https://seekingalpha.com/symbol/SST' title='SPDR Barclays Capital Short Term Treasury ETF'>SST</a>, <a href='https://seekingalpha.com/symbol/DTUS' title='iPath U.S. Treasury 2-Year Bear ETN'>DTUS</a>, <a href='https://seekingalpha.com/symbol/TUZ' title='PIMCO 1-3 Year U.S. Treasury Index ETF'>TUZ</a>, <a href='https://seekingalpha.com/symbol/DTUL' title='iPath U.S. Treasury 2-Year Bull ETN'>DTUL</a>, <a href='https://seekingalpha.com/symbol/RISE' title='Sit Rising Rate ETF'>RISE</a>, <a href='https://seekingalpha.com/symbol/GBIL' title='Goldman Sachs Treasury Access 0-1 year ETF'>GBIL</a>, <a href='https://seekingalpha.com/symbol/CLTL' title='PowerShares Treasury Collateral Portfolio ETF'>CLTL</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3294150-worlds-hated-asset-continues-gain\" target=\"_blank\">World's most hated asset continues to gain</a> (Sept. 7)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294146-financials-continue-lose-ground-banks-2-percent\" target=\"_blank\">Financials continue to lose ground; banks down more than 2%</a> (Sept. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294167\" data-linked=\"Rate hike odds disappear\" data-tweet=\"$SHY $VGSH $BIL - Rate hike odds disappear https://seekingalpha.com/news/3294167-rate-hike-odds-disappear?source=tweet\" data-url=\"https://seekingalpha.com/news/3294167-rate-hike-odds-disappear\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294133\" data-ts=\"1504796471\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294133-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/XOMA' title='XOMA Corporation'>XOMA</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/ADAP' title='Adaptimmune Therapeutics plc'>ADAP</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/LIFE' title='aTyr Pharma'>LIFE</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies Inc.'>ITCI</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/APOP' title='Cellect Biotechnology Ltd.'>APOP</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/CFRX' title='ContraFect Corp.'>CFRX</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/EXEL' title='Exelixis, Inc.'>EXEL</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294133\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$NLNK $XOMA $ADAP - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3294133-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3294133-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294159\" data-ts=\"1504796464\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294159-crude-futures-decline-post-inventory-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude futures decline further post inventory data</a></h4><ul>     <li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories</a>: Crude <strong>+4.6M</strong> barrels vs. +4.0M consensus, -5.4M last week.</li>     <li>Gasoline <strong>-3.2M</strong>&nbsp;vs. -5.0M consensus, +0.0M last week.</li>     <li>Distillates <strong>-1.4M</strong> barrels&nbsp;vs. -3.1M consensus, +0.7M last week.</li>     <li>Futures&nbsp;<font color='red'>-0.51%</font>&nbsp;to $48.91.</li>     <li>ETFs:<a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='PowerShares DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a></li>&nbsp; </ul><div class=\"tiny-share-widget\" data-id=\"3294159\" data-linked=\"Crude futures decline further post inventory data\" data-tweet=\"$USO $OIL $UCO - Crude futures decline further post inventory data https://seekingalpha.com/news/3294159-crude-futures-decline-post-inventory-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3294159-crude-futures-decline-post-inventory-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>74&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294154\" data-ts=\"1504795644\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HOFT\" target=\"_blank\">HOFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294154-on-hooker-furnitures-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Hooker Furniture&#39;s Q2</a></h4><ul><li>Hooker Furniture (<a href='https://seekingalpha.com/symbol/HOFT' title='Hooker Furniture Corporation'>HOFT</a> <font color='green'>+8.2%</font>)&nbsp;reports revenue growth of 15% in <a href=\"https://seekingalpha.com/pr/16934017-hooker-furniture-reports-double-digit-sales-profit-gains-second-quarter\" target=\"_blank\">Q2</a>,&nbsp;with sales up in all segments led by 20% improvement in&nbsp;Home Meridian&rsquo;s segment sales.</li><li>Net sales by segment:&nbsp;Hooker Casegoods: $34.88M (+3.9%);&nbsp;Upholstery: $22.36M (+12.7%);&nbsp;Home Meridian: $96.4M (+20%); All other: $2.66M (+12.2%).</li><li>Gross margin rate grew 30 bps to 21.2%.</li><li>SG&amp;A expense rate improved 90 bps to 13.4%.</li><li>Operating margin rate advanced 150 bps to 7.5%.</li><li>Inventories +6.7% Y/Y to $82.04M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294154\" data-linked=\"More on Hooker Furniture&#39;s Q2\" data-tweet=\"$HOFT - More on Hooker Furniture&#39;s Q2 https://seekingalpha.com/news/3294154-on-hooker-furnitures-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3294154-on-hooker-furnitures-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294150\" data-ts=\"1504794972\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294150-worlds-hated-asset-continues-to-gain\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">World&#39;s most hated asset continues to gain</a></h4><ul><li>The 10-year U.S. Treasury yield is threatening to drop below 2% for the first time since election night, off another 5.6 basis points today to 2.05%.</li><li>Pick your excuse: N. Korea, Irma, Harvey, asset market bubble concerns (<a href=\"https://blogs.wsj.com/moneybeat/2017/09/06/goldmans-blankfein-on-markets-things-have-been-going-up-for-too-long/\" target=\"_blank\">Goldman's Lloyd Blankfein is</a> the latest bigwig to publicly voice).</li><li>In case anyone hasn't been paying attention, the banking sector <a href=\"https://seekingalpha.com/news/3294146-financials-continue-lose-ground-banks-2-percent\" target=\"_blank\">has rolled over</a> in a big way - now underperforming the broader market by about 2000 basis points in 2017.</li><li>For the session: <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>&nbsp;<font color='green'>+1%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a><font color='red'> -2%</font>. TLT's YTD gain of<font color='green'> nearly 9%</font>&nbsp;now about matches that of the S&amp;P 500.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>, <a href='https://seekingalpha.com/symbol/TMV' title='Direxion Daily 20+ Year Treasury Bear 3x Shares ETF'>TMV</a>, <a href='https://seekingalpha.com/symbol/TBF' title='ProShares Short 20+ Year Treasury ETF'>TBF</a>, <a href='https://seekingalpha.com/symbol/EDV' title='Vanguard Extended Duration Treasury ETF'>EDV</a>, <a href='https://seekingalpha.com/symbol/TMF' title='Direxion Daily 30-Year Treasury Bull 3x Shares ETF'>TMF</a>, <a href='https://seekingalpha.com/symbol/TTT' title='ProShares UltraPro Short 20+ Year Treasury ETF'>TTT</a>, <a href='https://seekingalpha.com/symbol/ZROZ' title='PIMCO 25+ Year Zero Coupon U.S. Treasury Index ETF'>ZROZ</a>, <a href='https://seekingalpha.com/symbol/VGLT' title='Vanguard Long-Term Government Bond Index ETF'>VGLT</a>, <a href='https://seekingalpha.com/symbol/TLH' title='iShares 10-20 Year Treasury Bond ETF'>TLH</a>, <a href='https://seekingalpha.com/symbol/UBT' title='ProShares Ultra 20+ Year Treasury ETF'>UBT</a>, <a href='https://seekingalpha.com/symbol/TLO' title='SPDR Barclays Long Term Treasury ETF'>TLO</a>, <a href='https://seekingalpha.com/symbol/DLBS' title='iPath U.S. Treasury Long Bond Bear ETN'>DLBS</a>, <a href='https://seekingalpha.com/symbol/VUSTX' title='Vanguard Long Term Treasury Fund Inv'>VUSTX</a>, <a href='https://seekingalpha.com/symbol/TYBS' title='Direxion Daily 20+ Year Treasury Bear 1x Shares ETF'>TYBS</a>, <a href='https://seekingalpha.com/symbol/DLBL' title='iPath U.S. Treasury Long Bond Bull ETN'>DLBL</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3294150\" data-linked=\"World&#39;s most hated asset continues to gain\" data-tweet=\"$TLT $TBT $TMV - World&#39;s most hated asset continues to gain https://seekingalpha.com/news/3294150-worlds-hated-asset-continues-to-gain?source=tweet\" data-url=\"https://seekingalpha.com/news/3294150-worlds-hated-asset-continues-to-gain\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294149\" data-ts=\"1504794808\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBUU\" target=\"_blank\">MBUU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294149-malibu-boats-heads-higher-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Malibu Boats heads higher after earnings</a></h4><ul> <li>Malibu Boats (<a href='https://seekingalpha.com/symbol/MBUU' title='Malibu Boats, Inc.'>MBUU</a> <font color='green'>+2.1%</font>) trades higher after topping estimates with its FQ4 report.</li> <li>Unit volume was up 9% to 1,004 boats during the quarter. Net sales per unit increased 3.4% to $74,807.</li> <li>\"We continue to believe the decrease in retail sales over the previous two or three years has abated and we are now showing recovery at the retail level which we believe will lead to recovery at the wholesale level.\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294055-malibu-boats-beats-0_01-beats-revenue\" target=\"_blank\">Malibu Boats beats by $0.01, beats on revenue</a> (Sept. 7)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3294149\" data-linked=\"Malibu Boats heads higher after earnings\" data-tweet=\"$MBUU - Malibu Boats heads higher after earnings https://seekingalpha.com/news/3294149-malibu-boats-heads-higher-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3294149-malibu-boats-heads-higher-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:33 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294147\" data-ts=\"1504794665\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294147-natural-gas-inventory-build-par-consensus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natural gas inventory build at par with consensus</a></h4><ul>     <li><a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory</a>: <strong>+65 Bcf</strong> vs. +64 Bcf consensus, +30 Bcf last week.</li><li>Futures&nbsp;<font color='red'>-0.33%</font>&nbsp;to $2.990.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/GAZ' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a>,<a href='https://seekingalpha.com/symbol/DCNG' title='iPath Pure Beta Seasonal Natural Gas ETN'>DCNG</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294147\" data-linked=\"Natural gas inventory build at par with consensus\" data-tweet=\"$UNG $DGAZ $UGAZ - Natural gas inventory build at par with consensus https://seekingalpha.com/news/3294147-natural-gas-inventory-build-par-consensus?source=tweet\" data-url=\"https://seekingalpha.com/news/3294147-natural-gas-inventory-build-par-consensus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294146\" data-ts=\"1504794491\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/C\" target=\"_blank\">C</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294146-financials-continue-to-lose-ground-banks-down-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials continue to lose ground; banks down more than 2%</a></h4><ul><li>There's not a whole lot going on with the major averages this morning, but the financial sector is taking another beating, with the <a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>&nbsp;<font color='red'>down 1.5%</font>. The banks are even worse - the <a href='https://seekingalpha.com/symbol/KRE' title='SPDR S&P Regional Banking ETF'>KRE</a>&nbsp;<font color='red'>down 2.3%</font>, and <a href='https://seekingalpha.com/symbol/KBE' title='SPDR S&P Bank ETF'>KBE</a>&nbsp;<font color='red'>off 2.2%</font>.</li><li>The KRE is&nbsp;<font color='red'>lower by 10.5%</font>&nbsp;YTD, and the KBE&nbsp;<font color='red'>8%</font>&nbsp;- a whopping underperformance to the XLF's&nbsp;<font color='green'>3% advance</font>, and the S&amp;P 500's&nbsp;<font color='green'>10% gain</font>.</li><li>At least partly to blame is a sizable flattening in the yield curve - while the Fed has hiked twice this year, the 10-year yield has tumbled all the way to its current 2.05% (the lowest since the election) vs. its 2017 start around 2.45%.</li><li>Citigroup (<a href='https://seekingalpha.com/symbol/C' title='Citigroup Inc.'>C</a> <font color='red'>-2.1%</font>), Morgan Stanley (<a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a> <font color='red'>-2.2%</font>), U.S. Bancorp (<a href='https://seekingalpha.com/symbol/USB' title='U.S. Bancorp'>USB</a> <font color='red'>-1.7%</font>), Huntington Bancshares (<a href='https://seekingalpha.com/symbol/HBAN' title='Huntington Bancshares Incorporated'>HBAN</a> <font color='red'>-2.4%</font>), BB&amp;T (<a href='https://seekingalpha.com/symbol/BBT' title='BB&T Corporation'>BBT</a> <font color='red'>-2.3%</font>), SunTrust (<a href='https://seekingalpha.com/symbol/STI' title='SunTrust Banks, Inc.'>STI</a> <font color='red'>-2.5%</font>)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>, <a href='https://seekingalpha.com/symbol/FAS' title='Direxion Daily Financial Bull 3x Shares ETF'>FAS</a>, <a href='https://seekingalpha.com/symbol/FAZ' title='Direxion Daily Financial Bear 3x Shares ETF'>FAZ</a>, <a href='https://seekingalpha.com/symbol/VFH' title='Vanguard Financials ETF'>VFH</a>, <a href='https://seekingalpha.com/symbol/UYG' title='ProShares Ultra Financials ETF'>UYG</a>, <a href='https://seekingalpha.com/symbol/IYF' title='iShares U.S. Financials ETF'>IYF</a>, <a href='https://seekingalpha.com/symbol/FNCL' title='Fidelity MSCI Financials Index ETF'>FNCL</a>, <a href='https://seekingalpha.com/symbol/BTO' title='John Hancock Financial Opportunity Fund'>BTO</a>, <a href='https://seekingalpha.com/symbol/IYG' title='iShares U.S. Financial Services ETF'>IYG</a>, <a href='https://seekingalpha.com/symbol/FXO' title='First Trust Financials AlphaDEX ETF'>FXO</a>, <a href='https://seekingalpha.com/symbol/SEF' title='ProShares Short Financials ETF'>SEF</a>, <a href='https://seekingalpha.com/symbol/RYF' title='Invesco S&P Equal Weight Financial ETF'>RYF</a>, <a href='https://seekingalpha.com/symbol/FINU' title='ProShares UltraPro Financials ETF'>FINU</a>, <a href='https://seekingalpha.com/symbol/XLFS' title='Financial Services Select Sector SPDR ETF'>XLFS</a>, <a href='https://seekingalpha.com/symbol/FINZ' title='ProShares UltraPro Short Financials ETF'>FINZ</a>, <a href='https://seekingalpha.com/symbol/RWW' title='Oppenheimer Financials Sector Revenue ETF'>RWW</a>, <a href='https://seekingalpha.com/symbol/FAZZ' title='Direxion Daily Financial Bear 1x Shares ETF'>FAZZ</a>, <a href='https://seekingalpha.com/symbol/JHMF' title='John Hancock Multifactor Financials ETF'>JHMF</a>, <a href='https://seekingalpha.com/symbol/FNCF' title='iShares Edge MSCI Multifactor Financials ETF'>FNCF</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3294146\" data-linked=\"Financials continue to lose ground; banks down more than 2%\" data-tweet=\"$C $XLF $KRE - Financials continue to lose ground; banks down more than 2% https://seekingalpha.com/news/3294146-financials-continue-to-lose-ground-banks-down-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3294146-financials-continue-to-lose-ground-banks-down-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294139\" data-ts=\"1504793413\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLNT\" target=\"_blank\">FLNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294139-cogintplus-3_2-on-business-combination-bluefocus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cogint +3.2% on business combination with BlueFocus</a></h4><ul>     <li>Ad/marketing firm Cogint (COGT) is <font color='green'>up 3.2%</font> after announcing an <a href=\"https://seekingalpha.com/pr/16933691-cogint-announces-business-combination-bluefocus-creating-world-class-global-marketing\" target=\"_blank\">agreement to combine businesses</a> with China's BlueFocus and an intent to spin off part of the combination devoted to data and analytics.</li>     <li>In the deal, BlueFocus will bring $100M in cash and sub-agencies: Canada-based Vision7 International, UK-based We Are Very Social Limited, and Indigo Social. Cogint shareholders will own 37% of the combination, while BlueFocus' will own 63%.</li>     <li>The combined company is expected to see 2018 revenues of more than $500M and EBITDA of more than $75M.</li>     <li>The deal values Cogint's performance marketing business, Fluent, at $415M.</li>     <li>Just prior to closing, Cogint's data and analytics operations/assets will be spun into a company called Red Violet, expected to be listed on Nasdaq, and Red Violet's shares will be distributed to Cogint shareholders.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294139\" data-linked=\"Cogint +3.2% on business combination with BlueFocus\" data-tweet=\"$FLNT $RDVT - Cogint +3.2% on business combination with BlueFocus https://seekingalpha.com/news/3294139-cogintplus-3_2-on-business-combination-bluefocus?source=tweet\" data-url=\"https://seekingalpha.com/news/3294139-cogintplus-3_2-on-business-combination-bluefocus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294131\" data-ts=\"1504792156\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLY\" target=\"_blank\">LLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294131-lilly-to-streamline-business-axe-3500-jobs-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lilly to streamline business, axe 3,500 jobs; shares up 1%</a></h4><ul><li>With the aim of sharpening its focus on developing new medicines and improving its cost structure, Eli Lilly (<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a> <font color='green'>+0.9%</font>) <a href=\"https://seekingalpha.com/pr/16934308-lilly-takes-steps-streamline-business-invest-new-medicines-drive-growth\" target=\"_blank\">launches an initiative</a> to streamline its operations. The move will include the elimination of 3,500 positions, the majority of which will come from an early retirement offer in the U.S. that will be completed by year-end.</li><li>Changes in operations include the transfer of production of animal health products from Larchwood, IA to Fort Dodge, IA, the closure of an R&amp;D office in Bridgewater, NJ and the closure of the Lilly China Research and Development Center in Shanghai.</li><li>The company expects to trim $500M in annual operation expenses starting in 2018, equally split between cost structure improvement and reinvestment in the business. The savings will enable it to achieve an operating expense/revenue ratio of 49% or less next year.</li><li>It will record a ~$1.2B pre-tax charge ($0.80/share after tax) this year to account for the restructuring, special charges and asset impairment.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294131\" data-linked=\"Lilly to streamline business, axe 3,500 jobs; shares up 1%\" data-tweet=\"$LLY - Lilly to streamline business, axe 3,500 jobs; shares up 1% https://seekingalpha.com/news/3294131-lilly-to-streamline-business-axe-3500-jobs-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3294131-lilly-to-streamline-business-axe-3500-jobs-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294126\" data-ts=\"1504790913\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CETV\" target=\"_blank\">CETV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294126-central-european-media-gets-boost-from-index-inclusion\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Central European Media gets boost from index inclusion</a></h4><ul>   <li>Central European Media (NASDAQ:<a href='https://seekingalpha.com/symbol/CETV' title='Central European Media Enterprises Ltd.'>CETV</a>) is <font color='green'>up 2.4%</font> in premarket Nasdaq trading after word that it will be included in the Vienna CECE index.</li>    <li>Premarket quotes are at $4.20; shares in Prague were up 4.6% to an equivalent of $4.29.</li>    <li>Shares are <font color='green'>up 60.8%</font> YTD on Nasdaq.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294126\" data-linked=\"Central European Media gets boost from index inclusion\" data-tweet=\"$CETV - Central European Media gets boost from index inclusion https://seekingalpha.com/news/3294126-central-european-media-gets-boost-from-index-inclusion?source=tweet\" data-url=\"https://seekingalpha.com/news/3294126-central-european-media-gets-boost-from-index-inclusion\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294122\" data-ts=\"1504790655\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294122-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/RH' title='RH'>RH</a> <font color='green'>+40%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3293971-rh-soars-lifting-full-year-guidance\" target=\"_blank\">lifting</a> FY guidance.</li>     <li>CLNT <font color='green'>+33%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16933683-cleantech-solutions-international-enters-agreement-ecoin-development-development\" target=\"_blank\">entering</a> into an agreement for the&nbsp;development and operation of a cryptocurrency system to support the development of a sharing economy ecosystem based on blockchain solutions.</li>     <li><a href='https://seekingalpha.com/symbol/CAB' title='Cabela&#39;s Incorporated'>CAB</a> <font color='green'>+15%</font>&nbsp;on Fed approval <a href=\"https://seekingalpha.com/news/3293991\" target=\"_blank\">sale</a> of Cabela's credit-card unit.</li>     <li><a href='https://seekingalpha.com/symbol/ADAP' title='Adaptimmune Therapeutics plc'>ADAP</a> <font color='green'>+14%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16933822-gsk-exercises-option-spear-t-cell-therapy-program-targeting-ny-eso\" target=\"_blank\">exercising</a> its option under a collaboration and license agreement signed in 2014 to exclusively license the right to research, develop, and commercialize Adaptimmune&rsquo;s&nbsp;NY-ESO SPEAR T-cell therapy program.</li>     <li><a href='https://seekingalpha.com/symbol/GPRO' title='GoPro'>GPRO</a> <font color='green'>+13%</font>&nbsp;on&nbsp;updating Q3 <a href=\"https://seekingalpha.com/news/3294073\" target=\"_blank\">guidance</a>.</li>     <li><a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a> <font color='green'>+13%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16933724-updated-data-indoximod-plus-keytruda-pembrolizumab-demonstrate-improvement-response-rate\" target=\"_blank\">updated</a> data from the ongoing Phase 2 NLG2103 study of indoximod, NewLink Genetics&rsquo; IDO pathway inhibitor, in combination with the PD-1 pathway inhibitor, KEYTRUDA.</li>     <li><a href='https://seekingalpha.com/symbol/NXTD' title='NXT-ID Inc.'>NXTD</a> <font color='green'>+9%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16933833-bank-america-nxt-id-subsidiary-fitpay-collaborate-accelerate-wearable-iot-payment-adoption\" target=\"_blank\">agreement</a> to extend contactless payment capabilities to a range of new devices, giving Bank of America customers more payment options and accelerating the adoption of new payment devices.</li>     <li><a href='https://seekingalpha.com/symbol/CUR' title='Neuralstem, Inc.'>CUR</a> <font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3294092\" target=\"_blank\">announcement</a> of issuance of two U.S. patents.</li>     <li><a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a> <font color='green'>+7%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/ZAIS' title='ZAIS Group Holdings'>ZAIS</a> <font color='green'>+6%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='green'>+6%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/FEYE' title='FireEye, Inc.'>FEYE</a> <font color='green'>+5%</font>&nbsp;after Morgan Stanley <a href=\"https://seekingalpha.com/news/3294115-fireeye-4_6-percent-morgan-stanley-upgrade\" target=\"_blank\">upgrade</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294122\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$RH $SEII $CAB - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3294122-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3294122-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294121\" data-ts=\"1504790602\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADAP\" target=\"_blank\">ADAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294121-glaxo-all-in-ny-eso-spear-t-cell-therapy-adaptimmune-up-11-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Glaxo all in with NY-ESO SPEAR T-cell therapy; Adaptimmune up 11% premarket</a></h4><ul><li>Thinly traded Adaptimmune (NASDAQ:<a href='https://seekingalpha.com/symbol/ADAP' title='Adaptimmune Therapeutics plc'>ADAP</a>) jumps&nbsp;<font color='green'>11%</font>&nbsp;premarket on average volume on the heels of its <a href=\"https://seekingalpha.com/pr/16933822-gsk-exercises-option-spear-t-cell-therapy-program-targeting-ny-eso\" target=\"_blank\">announcement </a>that GlaxoSmithKline (NYSE:<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline'>GSK</a>) has exercised its option to exclusively research, develop and commercialize its NY-ESO SPEAR T-cell therapy.</li><li>Under the terms of the agreement, Adaptimmune will receive up to \u20a448M over the transition period (up to \u20a418M in development milestones plus an option payment of \u20a430M). Successful continuation of development and eventual commercialization will trigger additional milestone payments. After commercial launch, Adaptimmune will receive mid-single to low-double-digit royalties on net sales.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294121\" data-linked=\"Glaxo all in with NY-ESO SPEAR T-cell therapy; Adaptimmune up 11% premarket\" data-tweet=\"$ADAP $ADAP $GSK - Glaxo all in with NY-ESO SPEAR T-cell therapy; Adaptimmune up 11% premarket https://seekingalpha.com/news/3294121-glaxo-all-in-ny-eso-spear-t-cell-therapy-adaptimmune-up-11-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3294121-glaxo-all-in-ny-eso-spear-t-cell-therapy-adaptimmune-up-11-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294119\" data-ts=\"1504790453\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KEM\" target=\"_blank\">KEM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294119-kemetminus-7-on-news-of-8_4m-share-secondary-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KEMET -7% on news of 8.4M-share secondary offering</a></h4><ul>     <li>KEMET&nbsp;(NYSE:<a href='https://seekingalpha.com/symbol/KEM' title='KEMET Corp.'>KEM</a>) <font color='red'>-7.2%</font> premarket after reporting a <a href=\"https://seekingalpha.com/pr/16933428-kemet-corporation-announces-secondary-offering-selling-securityholder\" target=\"_blank\">secondary offering</a> of ~8.42M common shares via selling holders.</li>     <li>The shares to be offered are subject to issuance upon exercise of a warrant held by the selling security holder, an affiliate of Platinum  Equity Capital Partners II, that would be sold to and exercised by UBS, the underwriter in its sale of the underlying shares.</li><li>KEM would not receive any proceeds from the transaction, except for the underwriter&rsquo;s payment for the exercise of the warrant.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294119\" data-linked=\"KEMET -7% on news of 8.4M-share secondary offering\" data-tweet=\"$KEM - KEMET -7% on news of 8.4M-share secondary offering https://seekingalpha.com/news/3294119-kemetminus-7-on-news-of-8_4m-share-secondary-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3294119-kemetminus-7-on-news-of-8_4m-share-secondary-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>50&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294118\" data-ts=\"1504790341\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNC\" target=\"_blank\">GNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294118-gnc-holdings-looks-to-boost-china-business\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GNC Holdings looks to boost China business</a></h4><ul> <li>GNC Holdings (NYSE:<a href='https://seekingalpha.com/symbol/GNC' title='GNC Holdings, Inc.'>GNC</a>) is <a href=\"https://www.reuters.com/article/gnc-hldg-ma-china/supplements-retailer-gnc-seeks-china-partner-to-aid-turnaround-sources-idUSL4N1LM1ZD\" target=\"_blank\">looking</a> for a partner in China to help it increase sales, sources tell Reuters.</li> <li>The company is also expected to receive an offer this week from Harbin Gloria Pharmaceuticals as it strategic review of options continues.</li> <li>GNC hasn't issued a reply to the Reuters story.</li> <li>GNC <font color='green'>+4.25%</font> premarket to $8.59.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294118\" data-linked=\"GNC Holdings looks to boost China business\" data-tweet=\"$GNC - GNC Holdings looks to boost China business https://seekingalpha.com/news/3294118-gnc-holdings-looks-to-boost-china-business?source=tweet\" data-url=\"https://seekingalpha.com/news/3294118-gnc-holdings-looks-to-boost-china-business\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>52&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294117\" data-ts=\"1504790122\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIT\" target=\"_blank\">FIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294117-fitbitplus-3_6-on-glucose-monitoring-partnership\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fitbit +3.6% on glucose-monitoring partnership</a></h4><ul>   <li>Fitbit (NYSE:<a href='https://seekingalpha.com/symbol/FIT' title='Fitbit, Inc.'>FIT</a>) is teaming up with glucose-monitoring firm DexCom (NASDAQ:<a href='https://seekingalpha.com/symbol/DXCM' title='DexCom, Inc.'>DXCM</a>) to provide <a href=\"https://seekingalpha.com/pr/16934213-fitbit-dexcom-develop-continuous-glucose-monitoring-cgm-experience-people-living-diabetes\" target=\"_blank\">continuous glucose monitoring solutions</a> for those living with diabetes, starting with the new Ionic smartwatch.</li>    <li>Fitbit is <font color='green'>up 3.6%</font> premarket.</li>    <li>Using the Ionic, CGM users would be able to see activity and glucose levels on their wrist.</li>    <li>The solution will be available to Android and iOS users starting \"as soon as possible in 2018.\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292460-raymond-james-sees-promise-fitbits-smartwatch\" target=\"_blank\">Raymond James sees promise in Fitbit's smartwatch</a> (Aug. 29 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292076-fitbit-smartwatch-wireless-headphones-smart-scale-available-preorder\" target=\"_blank\">Fitbit smartwatch, wireless headphones, and smart scale available for preorder</a> (Aug. 28 2017)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294117\" data-linked=\"Fitbit +3.6% on glucose-monitoring partnership\" data-tweet=\"$FIT $FIT $DXCM - Fitbit +3.6% on glucose-monitoring partnership https://seekingalpha.com/news/3294117-fitbitplus-3_6-on-glucose-monitoring-partnership?source=tweet\" data-url=\"https://seekingalpha.com/news/3294117-fitbitplus-3_6-on-glucose-monitoring-partnership\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>42&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294116\" data-ts=\"1504790006\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294116-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/BKS' title='Barnes & Noble Inc'>BKS</a>&nbsp;<font color='red'>-12%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3294101-barnes-and-noble-misses-0_03-misses-revenue\" target=\"_blank\">Q1 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a>&nbsp;<font color='red'>-12%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3294061-alnylam-suspends-mid-stage-extension-study-hemophilia-candidate-fitusiran-patient-death\" target=\"_blank\">suspending</a> mid-stage extension study of hemophilia candidate fitusiran after patient death.</li><li><a href='https://seekingalpha.com/symbol/AM' title='Antero Midstream Partners'>AM</a>&nbsp;<font color='red'>-7%</font>&nbsp;after Antero Resources (NYSE:<a href='https://seekingalpha.com/symbol/AR' title='Antero Resources Corporation'>AR</a>) <a href=\"https://seekingalpha.com/news/3294113-antero-midstream-minus-7-percent-10m-unit-offering-priced-31_45\" target=\"_blank\">pricing</a> a public offering of 10M common units.</li><li><a href='https://seekingalpha.com/symbol/KEM' title='KEMET Corp.'>KEM</a> <font color='red'>-7%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16933428-kemet-corporation-announces-secondary-offering-selling-securityholder\" target=\"_blank\">announcing</a> secondary offering by selling securityholder.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3294116\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$BKS $ALNY $AM - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3294116-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3294116-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294115\" data-ts=\"1504789981\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FEYE\" target=\"_blank\">FEYE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294115-fireeye-up-4_6-after-morgan-stanley-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FireEye up 4.6% after Morgan Stanley upgrade</a></h4><ul><li>        FireEye (NASDAQ:<a href='https://seekingalpha.com/symbol/FEYE' title='FireEye, Inc.'>FEYE</a>) shares are&nbsp;<font color='green'>up 4.6%</font>&nbsp;premarket after a Morgan Stanley upgrade from Equal Weight to Overweight.</li><li>               Price target increased by $6 to $19.&nbsp;</li><li>               Analyst Milissa Franchi sees meaningful adoption signals of the Helix detection and response platform, which supports her $33 bull target.&nbsp;</li><li>               Source: <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Morgan+Stanley+Upgrades+FireEye%2C+Inc+%28FEYE%29+to+Overweight/13273008.html\" target=\"_blank\">StreetInsider</a>&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3294115\" data-linked=\"FireEye up 4.6% after Morgan Stanley upgrade\" data-tweet=\"$FEYE - FireEye up 4.6% after Morgan Stanley upgrade https://seekingalpha.com/news/3294115-fireeye-up-4_6-after-morgan-stanley-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3294115-fireeye-up-4_6-after-morgan-stanley-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294107\" data-ts=\"1504789788\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294107-astrazeneca-reports-positive-results-from-late-stage-study-of-duaklir-in-copd-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AstraZeneca reports positive results from late-stage study of Duaklir in COPD; shares ahead 2% premarket</a></h4><ul><li>AstraZeneca (NYSE:<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a>) is up&nbsp;<font color='green'>2%</font>&nbsp;premarket, stoked in large part by the previously announced positive results from the PATHWAY study, but it also has other <a href=\"https://www.astrazeneca.com/media-centre/press-releases/2017/duaklir-significantly-improves-lung-function-in-copd-patients-07092017.html\" target=\"_blank\">good news</a> this morning.</li><li>A Phase 3 study, AMPLIFY, assessing Duaklir (aclidinium bromide/formoterol fumarate for inhalation) in patients with chronic obstructive pulmonary disease &#40;COPD&#41; <a href=\"https://seekingalpha.com/pr/16933592-circassia-announces-duaklir-r-successfully-met-primary-endpoints-amplify-phase-iii-study\" target=\"_blank\">met its co-primary endpoints</a> demonstrating statistically significant and clinically meaningful improvements in lung function compared to the two active ingredients each administered as monotherapy.</li><li>Aclidinium monotherapy (Tudorza Pressair) demonstrated non-inferiority (no worse than) to Boehringer Ingelheim's Spiriva Handihaler (tiotropium). A sub-study of 24-hour bronchodilation showed statistically significant greater nighttime bronchodilation for twice-daily Duaklir and Tudorza compared to once-daily Spiriva.</li><li>Complete data will be submitted for presentation at a future medical conference.</li><li>Under an April 2017 collaboration agreement, UK-based Circassia Pharmaceuticals has exclusive commercialization rights to Duaklir in the U.S. and is also responsible for marketing Tudorza. AstraZeneca is responsible for development, including filing the NDA with the FDA, expected in H1 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294078-astrazenecas-tezepelumab-shows-significant-treatment-benefit-mid-stage-asthma-study-shares-1\" target=\"_blank\">AstraZeneca's tezepelumab shows significant treatment benefit in mid-stage asthma study; shares up 1% premarket</a> (Sept. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294107\" data-linked=\"AstraZeneca reports positive results from late-stage study of Duaklir in COPD; shares ahead 2% premarket\" data-tweet=\"$AZN - AstraZeneca reports positive results from late-stage study of Duaklir in COPD; shares ahead 2% premarket https://seekingalpha.com/news/3294107-astrazeneca-reports-positive-results-from-late-stage-study-of-duaklir-in-copd-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3294107-astrazeneca-reports-positive-results-from-late-stage-study-of-duaklir-in-copd-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294113\" data-ts=\"1504789674\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AM\" target=\"_blank\">AM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294113-antero-midstreamminus-7-after-10m-unit-offering-priced-31_45\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Antero Midstream -7% after 10M-unit offering priced at $31.45</a></h4><ul>     <li>Antero Midstream Partners (NYSE:<a href='https://seekingalpha.com/symbol/AM' title='Antero Midstream Partners'>AM</a>) <font color='red'>-7.1%</font> premarket after Antero Resources (NYSE:<a href='https://seekingalpha.com/symbol/AR' title='Antero Resources Corporation'>AR</a>) <a href=\"https://seekingalpha.com/pr/16933569-antero-resources-announces-pricing-secondary-offering-antero-midstream-partners-lp-common\" target=\"_blank\">prices a public offering</a> of 10M common units in the partnership at $31.45/unit; the underwriters also received a 30-day option to purchase up to an additional 1.5M units.</li>     <li>AR says it plans to use the net proceeds to <a href=\"https://seekingalpha.com/pr/16933354-antero-resources-announces-secondary-offering-antero-midstream-partners-lp-common-units\" target=\"_blank\">repay borrowings</a> under its credit facility; AM will not receive any of the expected ~$315M in aggregate gross proceeds from the offering.</li>          <li>Following the offering and assuming no  exercise of the underwriters' option, AR would own ~53% of the AM's outstanding common units.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294113\" data-linked=\"Antero Midstream -7% after 10M-unit offering priced at $31.45\" data-tweet=\"$AM $AM $AR - Antero Midstream -7% after 10M-unit offering priced at $31.45 https://seekingalpha.com/news/3294113-antero-midstreamminus-7-after-10m-unit-offering-priced-31_45?source=tweet\" data-url=\"https://seekingalpha.com/news/3294113-antero-midstreamminus-7-after-10m-unit-offering-priced-31_45\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294106\" data-ts=\"1504788824\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ITCI\" target=\"_blank\">ITCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294106-intra-cellular-therapies-announces-positive-topline-data-from-safety-switching-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intra-Cellular Therapies announces positive topline data from safety switching study with Lumateperone in patients with Schizophrenia; shares ahead 20% premarket</a></h4><ul> <li>Intra-Cellular Therapies (NASDAQ:<a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies Inc.'>ITCI</a>)&nbsp;<a href=\"https://seekingalpha.com/pr/16933755-intra-cellular-therapies-announces-positive-topline-data-6-week-open-label-safety-switching\" target=\"_blank\">announces</a> positive topline data from the first part of an open-label safety switching study in which 302 patients with stable symptoms of schizophrenia were switched from standard-of-care antipsychotic medications to lumateperone (ITI-007 60 mg) with no dose titration of lumateperone required for a 6-week treatment duration, then switched back to standard-of-care.</li>   <li>Many currently available antipsychotic agents are associated with motor side effects and/or weight gain, cardiovascular liabilities, dyslipidemia, and hyperglycemia.</li><li>In this study, lumateperone was generally well tolerated with a favorable safety profile. Statistically significant improvements from standard-of-care baseline were observed&nbsp;in body weight, cardiometabolic and endocrine parameters in patients when switched to lumateperone and worsened again when switched back to standard-of-care medication.</li><li>Additional data will be submitted for presentation at future medical conferences.</li><li>Shares are up&nbsp;<font color='green'>20%</font>&nbsp;premarket on light volume.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3294106\" data-linked=\"Intra-Cellular Therapies announces positive topline data from safety switching study with Lumateperone in patients with Schizophrenia; shares ahead 20% premarket\" data-tweet=\"$ITCI - Intra-Cellular Therapies announces positive topline data from safety switching study with Lumateperone in patients with Schizophrenia; shares ahead 20% premarket https://seekingalpha.com/news/3294106-intra-cellular-therapies-announces-positive-topline-data-from-safety-switching-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3294106-intra-cellular-therapies-announces-positive-topline-data-from-safety-switching-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294105\" data-ts=\"1504788367\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BKS\" target=\"_blank\">BKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294105-barnes-noble-drops-sharply-after-light-fq1-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barnes &amp; Noble drops sharply after light FQ1 sales</a></h4><ul> <li>Barnes &amp; Noble (NYSE:<a href='https://seekingalpha.com/symbol/BKS' title='Barnes & Noble Inc'>BKS</a>) falls short with <a href=\"https://seekingalpha.com/pr/16934052-barnes-and-noble-reports-fiscal-2018-first-quarter-financial-results\" target=\"_blank\">FQ1</a> sales as it shows a loss of $0.15 per share vs. $0.12 expected.</li> <li>The company cites lower online and Nook sales during the quarter.</li> <li>\"We expect to improve our performance in the back-half of the year, which coupled with our focus on expense reduction, will enable us to achieve EBITDA of $180 million,\" says CEO Demos Parneros.</li> <li>Looking ahead, B&amp;N expects comparable bookstore sales to fall at a low single-digit clip.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294101-barnes-and-noble-misses-0_03-misses-revenue\" target=\"_blank\">Barnes &amp; Noble misses by $0.03, misses on revenue</a> (Sept. 7)</li> <li>BKS <font color='red'>-10.19%</font> AH to $7.05.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294105\" data-linked=\"Barnes &amp; Noble drops sharply after light FQ1 sales\" data-tweet=\"$BKS - Barnes &amp; Noble drops sharply after light FQ1 sales https://seekingalpha.com/news/3294105-barnes-noble-drops-sharply-after-light-fq1-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3294105-barnes-noble-drops-sharply-after-light-fq1-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294103\" data-ts=\"1504788294\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294103-euro-breaks-through-1_20-draghi-speaks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Euro breaks through $1.20 as Draghi speaks</a></h4><ul><li>Recent euro (NYSEARCA:<a href='https://seekingalpha.com/symbol/FXE' title='CurrencyShares Euro Trust ETF'>FXE</a>) volatility is a source of uncertainty, says Mario Draghi, now speaking at his post-meeting press conference.</li><li><a href=\"https://www.ecb.europa.eu/home/html/index.en.html\" target=\"_blank\">Webcast</a></li><li>The euro has moved higher since he began talking, now&nbsp;<font color='green'>up 0.7%</font>&nbsp;and buying $1.20.</li><li>The ECB has revised downward its inflation expectations - now seeing 1.2% next year vs. 1.3% previously, and 1.5% in 2019 from 1.6% previously. Draghi says strength in the euro is behind the revisions.</li><li>The Stoxx 50 (NYSEARCA:<a href='https://seekingalpha.com/symbol/FEZ' title='SPDR EURO STOXX 50 ETF'>FEZ</a>) is<font color='green'> higher by 0.5%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294077-ecb-leaves-rates-unchanged\" target=\"_blank\">ECB leaves rates unchanged</a> (Sept. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294103\" data-linked=\"Euro breaks through $1.20 as Draghi speaks\" data-tweet=\"$FXE $FEZ - Euro breaks through $1.20 as Draghi speaks https://seekingalpha.com/news/3294103-euro-breaks-through-1_20-draghi-speaks?source=tweet\" data-url=\"https://seekingalpha.com/news/3294103-euro-breaks-through-1_20-draghi-speaks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294102\" data-ts=\"1504788226\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMY\" target=\"_blank\">BMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294102-opdivo-yervoy-combo-extends-survival-in-late-stage-kidney-cancer-study-bristol-myers-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Opdivo-Yervoy combo extends survival in late-stage kidney cancer study; Bristol-Myers up 2% premarket</a></h4><ul><li>Bristol-Myers Squibb (NYSE:<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a>) is up&nbsp;<font color='green'>2%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16933703-checkmate-minus-214-study-evaluating-opdivo-combination-yervoy-stopped-early-demonstrating\" target=\"_blank\">announcement</a> of positive results from a Phase 3 clinical trial, CheckMate-214, assessing the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) in treatment-naive patients with advanced/metastatic renal cell carcinoma &#40;RCC&#41;.</li><li>The study met its co-primary endpoint of demonstrating superior overall survival &#40;OS&#41; compared to sunitinib (Pfizer's SUTENT) in intermediate- and poor-risk patients. Specifically, the overall survival rate favored the Opdivo/Yervoy group 41.6% compared to 26.5%. Median duration of response was not reached for the combination (18.2 months for sunitinib). The other co-primary endpoint, progression-free survival &#40;PFS&#41;, favored the combination but fell short of statistical significance.</li><li>It also showed treatment with Opdivo/Yervoy improved OS in all randomized patients versus sunitinib.</li><li>The company plans to review the data with regulatory authorities and will include it in a presentation at ESMO later this week.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294102\" data-linked=\"Opdivo-Yervoy combo extends survival in late-stage kidney cancer study; Bristol-Myers up 2% premarket\" data-tweet=\"$BMY - Opdivo-Yervoy combo extends survival in late-stage kidney cancer study; Bristol-Myers up 2% premarket https://seekingalpha.com/news/3294102-opdivo-yervoy-combo-extends-survival-in-late-stage-kidney-cancer-study-bristol-myers-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3294102-opdivo-yervoy-combo-extends-survival-in-late-stage-kidney-cancer-study-bristol-myers-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294092\" data-ts=\"1504787277\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CUR\" target=\"_blank\">CUR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294092-neuralstem-announces-issuance-of-two-u-s-patents-shares-ahead-7-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neuralstem announces issuance of two U.S. patents; shares ahead 7% premarket</a></h4><ul> <li>Neuralstem (NYSEMKT:<a href='https://seekingalpha.com/symbol/CUR' title='Neuralstem, Inc.'>CUR</a>) has been <a href=\"https://seekingalpha.com/pr/16933779-neuralstem-announces-issuance-two-u-s-patents\" target=\"_blank\">awarded</a> two patents by the United States Patent and Trademark Office &#40;USPTO&#41;.</li>   <li>The first covers methods of treating neurodegenerative disorders through transplantation of neural stem cells while the second covers neural stem cells engineered to express IGF-1, a neurotrophic molecule with broad therapeutic potential in the treatment of neurodegenerative disorders.</li><li>Shares are up&nbsp;<font color='green'>7%</font>&nbsp;premarket on modest volume.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3294092\" data-linked=\"Neuralstem announces issuance of two U.S. patents; shares ahead 7% premarket\" data-tweet=\"$CUR $SNCA - Neuralstem announces issuance of two U.S. patents; shares ahead 7% premarket https://seekingalpha.com/news/3294092-neuralstem-announces-issuance-of-two-u-s-patents-shares-ahead-7-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3294092-neuralstem-announces-issuance-of-two-u-s-patents-shares-ahead-7-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294078\" data-ts=\"1504785623\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294078-astrazenecas-tezepelumab-shows-significant-treatment-benefit-in-mid-stage-asthma-study-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AstraZeneca&#39;s tezepelumab shows significant treatment benefit in mid-stage asthma study; shares up 1% premarket</a></h4><ul><li>AstraZeneca (NYSE:<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a>) and collaboration partner Amgen (NASDAQ:<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a>) <a href=\"https://seekingalpha.com/pr/16933451-tezepelumab-significantly-reduced-asthma-exacerbations-broad-population-patients-severe\" target=\"_blank\">announce</a> positive results from the Phase 2b PATHWAY study assessing tezepelumab in patients with severe uncontrolled asthma. The data, published today in the <em>New England Journal of Medicine</em>, showed treatment with tezepelumab, given as add-on therapy, reduced annual asthma exacerbation rates by as much as 71% versus placebo (p&lt;0.001).</li><li>Tezepelumab is a novel anti-thymic stromal lymphopoietin &#40;TSLP&#41; monoclonal antibody being developed by AZN's MedImmune, in collaboration with Amgen. TSLP is an upstream pro-inflammatory epithelial cytokine that plays a key role in a range of diseases, including asthma. Blocking TSLP may prevent the release of pro-inflammatory cytokines.</li><li>The development of tezepelumab is ongoing.</li><li>AZN is up&nbsp;<font color='green'>1%</font>&nbsp;and AMGN up a fraction premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294078\" data-linked=\"AstraZeneca&#39;s tezepelumab shows significant treatment benefit in mid-stage asthma study; shares up 1% premarket\" data-tweet=\"$AZN $AZN $AMGN - AstraZeneca&#39;s tezepelumab shows significant treatment benefit in mid-stage asthma study; shares up 1% premarket https://seekingalpha.com/news/3294078-astrazenecas-tezepelumab-shows-significant-treatment-benefit-in-mid-stage-asthma-study-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3294078-astrazenecas-tezepelumab-shows-significant-treatment-benefit-in-mid-stage-asthma-study-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294079\" data-ts=\"1504785369\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294079-ge-down-1_7-jpmorgan-turns-negative\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE down 1.7% as JPMorgan turns more negative</a></h4><ul><li><a href=\"https://twitter.com/thenotablecalls\" target=\"_blank\">via Notable Calls</a></li><li>The coming \"reset\" is going to be far worse than expected, says the team at JPMorgan. They see downside risk to their already well-below consensus estimates, driven by structural weakness in power, a less than hoped-for bounce in oil &amp; gas, and a more GAAP approach to reported numbers.</li><li>Outside of maybe Tyco in the late 90s, the team says it's never seen a large cap narrative go from $2+ EPS to something with a $1 handle and a risky dividend.</li><li>JPMorgan sees the stock headed to $17-$19 vs. last night's close of $24.92.</li><li><a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a>&nbsp;<font color='red'>-1.7%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3294079\" data-linked=\"GE down 1.7% as JPMorgan turns more negative\" data-tweet=\"$GE - GE down 1.7% as JPMorgan turns more negative https://seekingalpha.com/news/3294079-ge-down-1_7-jpmorgan-turns-negative?source=tweet\" data-url=\"https://seekingalpha.com/news/3294079-ge-down-1_7-jpmorgan-turns-negative\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>73&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294073\" data-ts=\"1504784507\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPRO\" target=\"_blank\">GPRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294073-gopro-shares-up-14_6-after-updating-q3-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GoPro shares up 14.6% after updating Q3 guidance</a></h4><ul><li>GoPro (NASDAQ:<a href='https://seekingalpha.com/symbol/GPRO' title='GoPro'>GPRO</a>) shares&nbsp;<font color='green'>up 14.6%</font>&nbsp;premarket after announcing an updated Q3 forecast.</li><li>GoPro expects revenue to come in between $290M and $310M, which comes in at the high end of the previous guidance and mostly exceeds the $304.04M consensus estimate.</li><li>GoPro expects gross margin between 36% and 38% and to be profitable on a non-GAAP basis the quarter.</li><li><a href=\"https://seekingalpha.com/pr/16933731-gopro-expects-third-quarter-2017-revenue-gross-margin-will-high-end-guidance\" target=\"_blank\">Press release</a></li><li>Correction: post updated to change headline wording.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294073\" data-linked=\"GoPro shares up 14.6% after updating Q3 guidance\" data-tweet=\"$GPRO - GoPro shares up 14.6% after updating Q3 guidance https://seekingalpha.com/news/3294073-gopro-shares-up-14_6-after-updating-q3-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3294073-gopro-shares-up-14_6-after-updating-q3-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294061\" data-ts=\"1504783254\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALNY\" target=\"_blank\">ALNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294061-alnylam-suspends-mid-stage-extension-study-of-hemophilia-candidate-fitusiran-after-patient\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alnylam suspends mid-stage extension study of hemophilia candidate fitusiran after patient death; shares down 23%</a></h4><ul><li>Alnylam Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a>) has <a href=\"https://seekingalpha.com/pr/16933736-alnylam-provides-pipeline-update-fitusiran-givosiran-investigational-rnai-therapeutic\" target=\"_blank\">suspended dosing</a> in its Phase 2 open-label extension study of RNAi therapeutic fitusiran for the treatment of hemophilia A and B with or without inhibitors. The company took action after a hemophilia A patient experienced a fatal thrombotic (blood clot) event.</li><li>About nine days prior to being admitted to the hospital, the patient developed exercise-induced right hip pain that was treated with three doses of factor VIII concentrate on three separate days. After receiving the third dose of factor VIII (four days prior to admission), he developed a severe headache and was subsequently diagnosed with a subarachnoid hemorrhage not related to fitusiran. Upon further review of the CT scans by radiologists, the diagnosis was changed to cerebral venous sinus thrombosis.</li><li>The company is reviewing the safety data and will develop a risk mitigation strategy. It expects to resume dosing after reviewing the data and protocol amendments with global regulatory authorities.</li><li>A Phase 3 study, ATLAS, has been initiated but not started yet.</li><li>The company will host a conference call this morning at 8:00 am ET to discuss the situation and update investors on its givosiran program.</li><li><strong>Update</strong>: Shares are down&nbsp;<font color='red'>23%</font>&nbsp;on resumption of trading.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294061\" data-linked=\"Alnylam suspends mid-stage extension study of hemophilia candidate fitusiran after patient death; shares down 23%\" data-tweet=\"$ALNY - Alnylam suspends mid-stage extension study of hemophilia candidate fitusiran after patient death; shares down 23% https://seekingalpha.com/news/3294061-alnylam-suspends-mid-stage-extension-study-of-hemophilia-candidate-fitusiran-after-patient?source=tweet\" data-url=\"https://seekingalpha.com/news/3294061-alnylam-suspends-mid-stage-extension-study-of-hemophilia-candidate-fitusiran-after-patient\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294049\" data-ts=\"1504782028\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALNY\" target=\"_blank\">ALNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294049-alnylam-trading-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alnylam trading halted pending news</a></h4><ul><li>Nasdaq <a href=\"http://www.nasdaqtrader.com/trader.aspx?id=tradehalts\" target=\"_blank\">suspends trading</a> in Alnylam Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a>) pending the release of news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294049\" data-linked=\"Alnylam trading halted pending news\" data-tweet=\"$ALNY - Alnylam trading halted pending news https://seekingalpha.com/news/3294049-alnylam-trading-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3294049-alnylam-trading-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294034\" data-ts=\"1504779652\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CONN\" target=\"_blank\">CONN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294034-on-conns-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Conn&#39;s Q2</a></h4><ul>     <li>Conn's (NASDAQ:<a href='https://seekingalpha.com/symbol/CONN' title='Conn&#39;s, Inc.'>CONN</a>) reports retail ame-store sales decreased 15.1% in <a href=\"https://seekingalpha.com/pr/16933673-conns-inc-reports-second-quarter-fiscal-year-2018-financial-results\" target=\"_blank\">Q2</a>.</li>     <li>Net sales by category:&nbsp;Furniture and mattress: $95.3M (-9.7%);&nbsp;Home appliance: $89.09M (-12.1%);&nbsp;Consumer electronics: $52.95M (-19.5%); Home office: $17.86M (-17.7%); Other: $4.4M (-17.9%);&nbsp;Repair service agreement commissions: $23.52M (-16.9%);&nbsp;Service revenues: $3.3M (-16.8%).</li>     <li>Credit revenue rose 21.9% to $80.1M.</li>     <li>Furniture unit volume fell 24.3% &amp; mattress unit volume contracted 15.9%.</li>     <li>Home appliance unit volume down 12%.</li>     <li>Consumer electronic&nbsp;unit volume declined 21.2%.</li>     <li>Home office unit volume slipped 13.2%.</li>     <li>Retail gross margin improved 270 bps to 39.8%.</li>     <li>Operating margin expanded 20 bps to 10.9%.</li>     <li>Retail store count +4 Y/Y to 116.</li>     <li>The Company is not providing specific financial guidance for Q3 because of the near-term uncertainty Harvey has created.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294034\" data-linked=\"More on Conn&#39;s Q2\" data-tweet=\"$CONN - More on Conn&#39;s Q2 https://seekingalpha.com/news/3294034-on-conns-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3294034-on-conns-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":68,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}